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ABSTRACT  
 
    Activation of the systemic inflammatory response is an essential part of effective host 
defence mechanism in sepsis. In certain circumstances the activation of inflammatory pathways 
can be excessive, and overactive proinflammatory response may trigger pathophysiologic 
mechanisms, which lead to the development of multiple organ failure (MOF). To ensure that the 
effects of proinflammatory response do not become destructive, the compensatory anti-
inflammatory response (CARS) is also activated in severe sepsis. The release of various anti-
inflammatory cytokines and the activation of hypothalamic–pituitary adrenal axis are major 
components of this response. These anti-inflammatory mechanisms may have an important role 
in the controlling proinflammatory reactions, but the clinical significance of this response in 
sepsis is not fully established. 
 
The objective of the present study was to evaluate the clinical significance of the compensatory 
anti-inflammatory response in severe sepsis and septic shock. The specific objectives were to 
investigate the role of relative adrenal insufficiency in the development and resolution of 
multiple organ failure (study I), to study the role of anti-inflammatory cytokine response in the 
pathogenesis of multiple organ failure (study II), to investigate changes in adrenocortical 
function in critically ill patients (study III) and to study the hemodynamic and metabolic effects 
of hydrocortisone therapy in septic shock (study IV). 
 
One-hundred-seventy-three critically ill patients were included in the study. Adrenal 
insufficiency was detected in 22% of the patients with severe sepsis and 40% of septic shock 
patients. In severe sepsis, impaired adrenal function was associated with a poor resolution of 
multiple organ failure. In patients with severe multiple organ failure the IL-6/IL-10 ratio was 
significantly higher in the early phase of sepsis compared to those patients who did not develop 
MOF. In the identification of adrenal insufficiency, the current diagnostic methods turned to be 
unsatisfactory. Especially in septic shock a single ACTH stimulation test could not reveal 
accurately those patients who had impaired adrenal function, and the results of the two 
consecutive ACTH tests were poorly reproducible. 
 
This study demonstrated that both adequate adrenal function and IL-10 response seemed to have 
an important protective function in the pathophysiology of sepsis and MOF. In septic shock the 
changes in adrenocortical function were very rapid and the single ACTH test was not reliable 
method in detecting adrenal insufficiency. In the treatment of septic shock, continuous 
hydrocortisone infusion was more effective in the maintenance of strict normoglycemia than 
conventional bolus treatment. 
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Medical Subject Headings: Adrenal Cortex; Adrenal Insufficiency; Adrenocorticotropic 
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1. INTRODUCTION 
 
Severe sepsis and septic shock are major challenges in intensive care (ICU) units. 
Despite the development of critical care medicine, the mortality from sepsis has 
remained considerably high. Severe sepsis is associated with a mortality rate of 25 - 
30% and in septic shock the hospital mortality is still 40 - 70% (Bernard 2001, Rivers 
2001, Dellinger 2003). Severe sepsis and septic shock are frequent causes of death in 
intensive care units and in 2001, severe sepsis and septic shock were responsible for 
approximately 750 000 hospital admissions and 210 000 deaths in United States (Angus 
2001). Recent epidemiological population-based studies suggest that sepsis is becoming 
more common (Martin 2003, Brun-Buisson 2004).  In Finland, the incidence of severe 
sepsis in ICUs is 0.38 / 1000 in the adult population (Karlsson 2007). 
 
In addition to high mortality, patients with sepsis consume a considerable amount of 
ICU resources and the cost associated with sepsis are substantial (Angus 2001, Weycker 
2003, Brun-Buisson 2004).  Especially the development of multiple organ failure 
(MOF) causes significant prolongation of ICU stay, and MOF further worsens patients´ 
prognosis (Beal 1994, Vincent 1998). A better understanding about the pathophysiology 
of sepsis has demonstrated that microbes themselves do not cause multiple organ 
failure, but rather infection initiates underlying host reactions, which cause endothelial 
damage, increased vascular permeability, activation of intravascular coagulation and 
apoptosis that ultimately lead to the development of progressive organ dysfunction. 
 
A prolonged and amplified systemic inflammatory response (SIRS) and concomitant 
release of proinflammatory cytokines has been traditionally considered to be a central 
pathophysiologic mechanism in the development of multiple organ failure in sepsis 
(Pinsky 1993). The concept of uncontrolled inflammation behind MOF has led to the 
numerous clinical trials which aimed at blocking various proinflammatory cascades in 
the early phase of sepsis. The results of these studies consistently failed to show any 
benefit of the immunomodulatory therapies. These findings have led to a re-evaluation 
of the model of sepsis.  
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Recent studies have suggested that sepsis is a bimodal entity. In addition to the 
activation of the inflammatory response, numerous anti-inflammatory reactions are 
launched during sepsis and the production and release of cytokine receptor antagonists, 
the soluble cytokine receptors and the anti-inflammatory cytokines are enhanced (Opal 
2000). Sepsis also causes numerous endocrinological alterations. Especially the 
activation of the hypothalamopituitary-adrenal-axis has an important role in the 
regulation of the inflammatory response (Chrousos 1995, Beishuizen 2004). These anti-
inflammatory responses control the magnitude of the inflammatory reactions. In clinical 
sepsis pro- and anti-inflammatory mechanisms are linked and interrelated to each other, 
forming a complex interactive network of endogenous immunological host reactions.  
 
The anti-inflammatory reactions in sepsis have been named as compensatory anti-
inflammatory response syndrome (CARS) by Roger Bone, inventor of the SIRS concept 
(Bone 1996). In theory, it is possible that anti-inflammatory reactions may have an 
important role in controlling inflammatory reactions, but the clinical significance of 
these reactions is so far not fully understood. In some studies anti-inflammatory 
reactions are considered to be protective (Taniguchi 1999). In other studies magnitude 
of anti-inflammatory response have been associated with profound immunosuppression 
and increased mortality (Gogos 2000).  
 
In this study, the aim was to further investigate the clinical significance of anti-
inflammatory mechanisms in severe sepsis and septic shock. Special attention was 
focused on the role of anti-inflammatory cytokines IL-10 and IL-1ra and endogenous 
cortisol production in the pathogenesis of multiple organ failure and changes in 
adrenocortical function in severe sepsis and septic shock. The second purpose in this 
study was to investigate different hydrocortisone treatment modalities and their 
metabolic and hemodynamic effects in the treatment of septic shock. 
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2. REVIEW OF LITERATURE 
 
2. 1. Systemic inflammatory response and sepsis  
 
Definition of sepsis 
 
Sepsis is defined as the systemic inflammatory response to infection (American College 
of Chest Physicians / Society of Critical Care Medicine Consensus Conference 1992). 
This definition was introduced by the American College of Chest Physicians and the 
Society of Critical Care Medicine consensus conference in 1991.  Before this consensus 
conference the terms sepsis, bacteremia, septicemia and sepsis syndrome were used 
interchangeably to characterize patients with severe generalized infection. The need for 
firm and generally accepted  definitions became apparent when studies assessing the 
effect of high-dose corticosteroid therapy in the treatment of sepsis were published in 
the 1980s (Sprung 1984, Bone 1987, VASSCS 1987). At that time point, the 
heterogeneity of the study populations and the absence of uniform definitions of sepsis 
prevented comparison of the study results. 
 
In the ACCP / SCCM consensus conference, new definitions for sepsis were agreed. 
According to these guidelines, sepsis was defined as a systemic response to infection 
and the conference proposed a new term, systemic inflammatory response syndrome 
(SIRS) to describe inflammatory process that occurs in conjunction with generalized 
infection (Bone 1992). The systemic inflammatory response syndrome has several 
clinical manifestations, including abnormalities of body temperature, respiratory rate, 
heart rate and leukocyte count. In addition to SIRS criteria, the consensus conference set 
the definitions for severe sepsis, septic shock and multiple organ dysfunction syndrome. 
These definitions are presented in the Table 1. In 2001 American and European critical 
care societies re-examined the 1991 ACCP/SCCM consensus conference definitions. 
The conclusion was that the concepts based on SIRS, although overly sensitive and 
nonspecific, are still useful in the diagnosis of sepsis and septic shock (Levy 2003). 
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Table 1. ACCP/SCCM consensus conference criteria for the systemic inflammatory response syndrome, 
sepsis, severe sepsis and septic shock. 
 
Term Definition 
SIRS Systemic inflammatory response syndrome. The systemic inflammatory response is 
manifested with two or more of the following criteria: 
Fever (body temperature > 38°C) or hypothermia (body temperature < 36°C) 
Tachycardia (heart rate >90 beats/min)  
Tachypnea (>20 breaths/min) or PaCO2 < 4.3 kPa 
Leukocytosis or leukopenia (white blood cell count > 12,000 or < 4,000/mm3) or > 
10% immature forms 
 
Sepsis 
 
Presence of SIRS in response to infection. SIRS in manifested by two or more of 
the criteria mentioned above 
 
Severe Sepsis 
 
Sepsis associated with organ dysfunction, hypoperfusion or hypotension. Organ 
dysfunction and hypoperfusion abnormalities may include, but are not limited to 
lactic acidosis, oliguria, or an alteration in mental status 
  
Septic shock Sepsis with hypotension despite adequate fluid resuscitation, along with the 
presence of perfusion abnormalities. Hypotension is defined as a systolic blood 
pressure < 90 mmHg or a decrease of systolic blood pressure by 40 mmHg or more 
from the baseline 
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Epidemiology of SIRS 
 
SIRS, sepsis, severe sepsis and septic shock represent the continuum of the same 
systemic response with increasing severity of the disease process. Using the 
ACCP/SCCM definitions, Rangel-Frausto et al. provided evidence of a clinical 
progression from SIRS to sepsis and further to severe sepsis and septic shock. In three 
intensive care units and three general wards 26 per cent of the patients with SIRS 
developed sepsis, 18% severe sepsis and 4% septic shock (Rangel-Frausto 1995).  44% 
to 71% of patients in any category demonstrated a disease progression from a one state 
of to another. Furthermore, a stepwise increase in mortality was observed as the disease 
process progressed from SIRS to sepsis, to severe sepsis and to septic shock. The 
mortality rates were 7% in patients with SIRS, 16% in patients with sepsis, 20% in 
severe sepsis and 46% in septic shock. A similar progressive increase in mortality from 
SIRS to sepsis to severe sepsis and to septic shock was observed in the epidemiological 
study performed in 99 Italian intensive care units (Salvo 1995). The mortality rates in 
this study were 27%, 36%, 52% and 82%, respectively. 
 
Since the ACCP/SCCM consensus conference the SIRS concept has been implemented 
into critical care terminology worldwide. Despite the general agreement, however, the 
concept has raised extensive criticism. Several authors have emphasized that significant 
limitations exist in the application of sepsis definitions into clinical practice (Salvo 
1995, Opal 1998). The definitions of SIRS are broad, and the clinical manifestations of 
the systemic inflammatory response are sensitive, but at the same time the specificity is 
very poor. SIRS can be triggered either by an infectious agents but also a numerous 
noninfectious insults can launch cascades that results to the development of SIRS. The 
majority of the ICU patients and patients with trauma, recent surgery, myocardial 
infarction or pulmonary embolism meet SIRS criteria without any evidence of sepsis 
(Muckart 1997, Pittet 1995, Vincent 1997). Bossink et al. demonstrated that 95% of the 
febrile medical patients met the two or more clinical criteria for SIRS, but only 44% of 
the patients developed sepsis (Bossink 1998). Pittet et al. demonstrated similar figures 
in surgical patients (Pittet 1995). Table 2 summarizes clinical frequencies of SIRS, 
sepsis, severe sepsis and septic shock. Because of poor specificity it has been suggested 
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that SIRS criteria in the diagnosis of sepsis can be misleading and potentially even 
harmful (Vincent 1997). The presence of infection is a fundamental part of the 
pathophysiology of sepsis, and sepsis should be only diagnosed at the presence of SIRS 
when infection is confirmed or strongly suspected. However, in 30% of patients the 
definitive origin of infection cannot be determined (Brun-Buisson 1995). 
 
 
Table 2. Clinical frequency of SIRS, sepsis, severe sepsis and septic shock. 
 
Reference No patients SIRS Sepsis Severe sepsis Septic shock 
Rangel-Frausto 1995 3 708 68% 18% 13% 3.0% 
Salvo 1995 1 101 58% 16% 5.5% 6.1% 
Pittet 1995 170 74% 19% 12% 5.3% 
Muckart 1997 450 88% 14% 14% 20% 
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2.2. Pathophysiology of SIRS 
 
Activation of innate and adaptive immunity 
 
Activation of the systemic inflammatory response is needed for effective host defense 
against infection. Multiple inflammatory pathways are activated in the initial stage of 
sepsis in order to handle the bacterial invasion. These mechanisms include the release of 
cytokines, activation of neutrophils, monocytes, macrophages and endothelial cells, and 
activation of complement, coagulation, fibrinolytic and contact systems (Hack 2000). 
The release of tissue-damaging proteinases, eicosanoids and oxygen and nitrogen 
radicals are also enhanced as a part of effective host defense mechanisms (Hack 2000). 
 
Toll-like receptors regulate antimicrobial host defense mechanisms and play a central 
role in the activation of innate immunity (Kopp 1999). Toll-like receptors are a family 
of cellular surface protein receptors that recognize molecular components of various 
micro-organisms. Bacterial components including lipopolysaccharide, lipoteichoic acid, 
flagellin and other cell wall components interact with Toll-like receptors and different 
microbial products bind to different receptors. TLR2 and TLR6 has been shown to react 
with lipoteichoic acid, TLR4 with lipopolysaccharide, and TLR5 with flagellin (Warren 
2005). These findings implicate that the innate immune response is tailored in a 
pathogen specific manner (Kopp 1999). 
 
In the initial phase of infection Toll-like receptors active innate immune system and 
invading pathogens are destroyed by macrophages, natural killer cells and complement 
system. In the second phase, Toll-like receptors from an important link between innate 
and adaptive immunity, and these receptors activate adaptive immune system by 
activating T and B lymphocytes (Modlin 2000). In this process, cytokine production has 
a fundamental role. Cytokines are endogenous immunomodulating proteins which have 
important role in the activation and regulation of various inflammatory reactions. 
Numerous host cells are capable of secreting cytokines upon stimulation. Activated 
macrophages and monocytes are the primary cells that produce cytokines but 
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fibroblasts, neutrophils and endothelial cells are also involved in the production of 
cytokines (Hack 1997).  
 
Cytokines usually influence adjacent cells, but they can also have actions throughout the 
body or on the secreting cell itself. Cytokine signaling is in most conditions a local 
process, but once cytokines access to the bloodstream, they can induce a systemic 
response. Cytokines can be classified into proinflammatory and anti-inflammatory 
cytokines depending on their principal function, but many cytokines have pleiotropic 
effects (Hack 2000). As more and more studies are available, it has become evident that 
the majority of proinflammatory cytokines have also anti-inflammatory properties and 
vice versa (Opal 2000). The net effect of any cytokine is dependent on the timing of 
cytokine release, the local milieu in which it acts, the presence of competing or 
synergistic elements, cytokine receptor density, and tissue responsiveness to a specific 
cytokine (Opal 2000).  
 
The most extensively studied cytokines in sepsis are TNF-Į, IL-1, IL-6, IL-8 IL-10 and 
IL-1ra, but also large number of other cytokines (IL-4, IL-12, IF-Ȗ, LIF, MIF, G-CSF, 
GM-CSF, HMGB-1) are involved in the pathogenesis of sepsis (Hack 1997, Yang 
2001). The central cytokines and their main actions in the pathophysiology of sepsis are 
presented in the Table 3. 
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Table 3. Principal cytokines and their actions in sepsis. 
 
Cytokine Nature Main source Principal actions 
TNF-Į proinflammatory 
monocytes 
macrophages 
- activates release of other 
proinflammatory cytokines 
- activates coagulation and complement 
systems 
- activates adhesion molecule synthesis 
IL-1ȕ proinflammatory 
 
monocytes 
macrophages 
- physiological actions similar and 
overlapping with TNFĮ 
- together with TNFĮ exerts synergistic 
effects  
IL-6 
proinflammatory 
anti-inflammatory 
 
 
monocytes 
macrophages 
endothelial cells 
- regulates B and T lymphocyte 
differentiation 
- stimulates synthesis of acute phase 
proteins 
- inhibits production of proinflammatory 
cytokines 
- activates HPA axis 
IL-8 
proinflammatory 
anti-inflammatory 
monocytes 
macrophages 
endothelial cells 
epithelial cells 
- induction of chemotaxis 
- activates neutrophils 
- regulates neutrophil migration  
IL-1ra anti-inflammatory 
monocytes 
macrophages 
- inhibits activity of IL-1 
IL-10 anti-inflammatory 
lymphocytes 
monocytes  
macrophages 
- inhibits production of proinflammatory     
cytokines 
- stimulates Th2-mediated immunity 
- regulates T and B cell proliferation 
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Proinflammatory cytokines 
 
Tumor necrosis factor alpha (TNF-D) and interleukin-1E (IL-1E) are the principal 
proinflammatory cytokines that are responsible for the initial activation of the systemic 
inflammatory response in sepsis (Hack 1997). Although these cytokines bind to 
different cellular receptors, they have multiple overlapping and synergistic effects in 
inflammation (Waage 1988). Both of these cytokines have powerful proinflammatory 
effects. Especially TNF-Į is considered to be extremely cytotoxic. TNF-Į is produced 
mainly by monocytes and macrophages. TNF-Į induces the production of adhesion 
molecules in endothelial cells, it activates the production of various other cytokines like 
IL-6 and IL-8 and it also activates coagulation and complement systems (van der Poll 
1990, Dinarello 1997). Administration of TNF-Į have resulted in fever, tachycardia, 
hypotension, leukocytosis or leucopenia, elevated liver enzymes, elevated creatinine 
levels and coagulopathy, all typical features in septic shock (Tracey 1986, Natanson 
1989). In experimental sepsis, the neutralization of TNF-Į with monoclonal antibodies 
has prevented the development of shock and death (Beutler 1985). 
 
In experimental sepsis, the peak concentrations of TNF-Į are detected very early after 
the administration of endotoxin, and no detectable concentrations of TNF-Į are 
observed after 10 hours period due to short half-life of TNF-Į (Michie 1988, Hack 
2000). In clinical sepsis, Waage et al. were first to demonstrate increased circulating 
TNF-Į levels in 30% of patients with severe meningococcal disease (Waage 1987). 
Furthermore, increased plasma levels of TNF-Į correlated with patient outcome (Waage 
1987). Increased TNF-Į levels generally correlate with the severity of illness, but there 
are also studies that have failed to confirm any correlation between elevated TNF-Į 
levels and patients´ prognosis (Damas 1992, Pinsky 1993, Casey 1993, Martin 1994). 
An evident reason of this discrepancy is the very short half-life of TNF-Į, which makes 
the timing of the cytokine samples very crucial. 
 
Together with TNF-Į, interleukin-1 (IL-1) is considered to be a central endogenous 
proinflammatory mediator in sepsis. IL-1 is mainly produced by monocytes and 
macrophages (Dinarello 1991). IL-1 consists of two structurally related cytokines IL-1Į 
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and IL-1ȕ. IL-1Į is very rarely found in circulation, and IL-1Į functions mainly as an 
intracellular messenger (Dinarello 1991). In contrast to IL-1Į, IL-1ȕ is released into to 
extracellular space. The biologic actions of IL-1E are similar to TNF-Į, and these two 
cytokines have a synergistic effect (Waage 1988). IL-1E induces the secretion of other 
cytokines including IL-6, IL-8 and TNF-Į, and it is capable to induce hemodynamic 
changes similar to septic shock (Dinarello 1991).  In experimental sepsis circulating IL-
1ȕ reach the peak levels after 2-3 h after the endotoxin challenge (Granowitz 19991). 
The half life of IL-1ȕ is very short and in clinical sepsis IL-1E levels are often 
undetectable (Cannon 1990). In most studies, IL-1ȕ levels have correlated very poorly 
with the severity of the disease (Damas 1992, Pinsky 1993, Casey 1993 Goldie 1995).  
 
 
Multimodal cytokines  
 
Interleukin-6 (IL-6) is the most extensively studied cytokine in sepsis. IL-6 levels are 
elevated for a longer period of time than TNF-Į and IL-1ȕ. In most studies IL-6 levels 
are significantly elevated in the majority of patients with sepsis. IL-6 is produced 
mainly by monocytes, macrophages and endothelial cells, but virtually every cell in the 
body can synthesise IL-6 upon appropriate stimulation (Hack 1997). TNF-Į, IL-1 and 
endotoxin are the main inducers of IL-6 production (Hack 2000) 
 
In several studies, the circulating IL-6 levels correlate well with the severity of sepsis 
(Hack 1989, Calandra 1991, Damas 1992), and the persistently high levels of IL-6 seem 
to associate with the development of MOF and poor prognosis (Pinsky 1993). Although 
elevated IL-6 levels associate with increased mortality in sepsis, the exact role of IL-6 
in the pathogenesis of sepsis is not clear (Hack 1997). IL-6 is relatively non-toxic 
cytokine. It does not activate neutrophils or endothelial cell and it does not induce a 
septic shock-like state (Preiser 1991). IL-6 regulates the growth of various cells, 
especially the differentiation of B and T lymphocytes (Hack 1997). IL-6 is an 
endogenous pyrogen, and fever in patients with sepsis may be induced by IL-6 
(Dinarello 1997). IL-6 plays a major role as a mediator of the acute-phase response, and 
it induces the synthesis of acute-phase proteins in liver. In sepsis, elevated IL-6 levels 
 26
reflect the activation of inflammatory response, and IL-6 is considered to be an alarm 
hormone during inflammation (Hack 1989).  IL-6 has also specific anti-inflammatory 
properties (Xing 1998). IL-6 inhibits the production of other proinflammatory cytokines 
and an adequate IL-6 response may also have important role in the activation of the 
hypothalamic-pituitary-adrenal axis in critical illness (Chrousos 1995, Xing 1998). 
 
Interleukin-8 (IL-8) is a prototype of a chemotactic cytokine. The primary function of 
IL-8 is to activate and chemoattract neutrophils to the sites of inflammation (Hack 
1997). Monocytes, macrophages, neutrophils, endothelial and epithelial cells are able to 
synthesize IL-8 and IL-8 production is also enhanced by other proinflammatory 
cytokines (Hack 1997). Endotoxin, TNF-Į and IL-1ȕ are major activators of IL-8 
production. In addition to the inflammatory mediators, also thrombin, ischemia and 
reperfusion can activate IL-8 release (Colotta 1994, Metinko 1992). IL-8 regulates 
leukocyte activation and migration during inflammation. Neutrophils are highly specific 
target cells for IL-8, but the role of IL-8 to the neutrophils is pivotal. High local 
concentrations of IL-8 induce neutrophil infiltration, endothelial damage, plasma 
leakage, and the development of local tissue injury (Colditz 1989). In contrast, high 
circulating intravascular IL-8 levels inhibit the migration of neutrophils in the tissues 
and IL-8 therefore has both anti- and proinflammatory properties, depending mainly on 
the site of its production (Hechtman 1991). Administration of IL-8 causes transient 
leukopenia, but it does not induce hemodynamic or metabolic alterations of sepsis, and 
it cannot induce septic shock state (Hack 1997).  
 
 
Anti-inflammatory cytokines  
 
In addition to proinflammatory cytokines, sepsis also activates the production and 
release of specific anti-inflammatory substances, including cytokine receptor 
antagonists, soluble cytokine receptors and anti-inflammatory cytokines (Granowitz 
1991, Goldie 1995, Opal 2000). Interleukin-1 receptor antagonist (IL-1ra) is a naturally 
occurring inhibitor of IL-1, which competitively binds to the IL-1 receptor and inhibits 
the actions of IL-1 (Dinarello 1991). IL-1ra attenuates endotoxin effects in animal 
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models of sepsis, and it also reduces mortality (Fischer 1992). IL-1ra is produced 
mainly by macrophages. In experimental sepsis, the concentrations of circulating IL-1ra 
are 100-fold higher than those of IL-1ß (Granowitz 1991). Although IL-1ra reduces 
mortality in experimental endotoxemia, its clinical relevance of IL-1ra production in 
sepsis is still unclear. Trials using exogenous IL-1ra in clinical sepsis have failed to 
demonstrate a definitive improvement in mortality (Fisher 1994, Opal 1997). 
 
Interleukin-10 (IL-10) is considered to be a central anti-inflammatory cytokine. IL-10 
was initially characterized as a cytokine that inhibited interferon (IFN)-Ȗ synthesis, but 
IL-10 also has other important down-regulatory functions in relation to other 
proinflammatory cytokines (Fiorentino 1991). IL-10 inhibits the production of TNF-Į, 
IL-1ȕ, IL-6 and IL-8 (Moore1993, Asadullah 2003). IL-10 suppresses free oxygen 
radical release and nitric oxide activity of macrophages and the production of 
prostaglandins (Goldman 1996). A major stimulus for the production of IL-10 is 
inflammation itself, and IL-1E and TNF-Į can stimulate IL-10 production directly 
(Hack 1997). Several cell types can produce IL-10, including CD4+ and CD8+  T cells, 
macrophages, monocytes, B cells, dendritic cells and epithelial cells (Moore 1993). In 
septic shock, monocytes are a major source of IL-10 (Goldman 1996). 
 
IL-10 not only limits the magnitude of the inflammatory response, but it also regulates 
the proliferation of T cells, B cells, natural killer cells, antigen-presenting cells, mast 
cells, and granulocytes (Asadullah 2003). IL-10 is a pluripotent cytokine that is 
considered to be an important molecule in immunoregulation and modulation of host 
defence reactions. IL-10 mainly mediates suppressive functions, but IL-10 also has 
stimulatory properties of innate immunity and of Th2-related immunity (Asadullah 
2003). In animal models of septic shock, administration of IL-10 has prevented 
endotoxin-induced mortality (Howard 1993). Several studies have documented elevated 
plasma IL-10 concentrations in sepsis (Marchant 1994, Derx 1995, Gogos 2000). In 
septic shock IL-10 levels are higher than in sepsis (Derkx 1995). Moreover, IL-10 levels 
have correlated positively with levels of proinflammatory cytokines and the severity of 
the septic shock (Friedman 1997).  
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2.3 Immunomodulatory trials 
 
After the discovery of proinflammatory cytokines, sepsis was considered to be 
fundamentally a disease caused by uncontrolled inflammation. In several studies 
increased levels of proinflammatory cytokines were reported to correlate with the 
severity of sepsis (Hack 1989, Damas 1992, Martin 1994, Goldie 1995), and especially 
persistently high levels of IL-6 were associated with the development of MOF and poor 
prognosis (Pinsky 1993). 
 
In 1985 Beutler, Milsark and Cerami demonstrated for the first time that neutralization 
of endogenous TNF by infusing antibodies against TNF was protective in experimental 
septic shock (Beutler 1985). This finding led to substantial boost in investigations that 
were able to demonstrate that the inhibition of various inflammatory mediators had 
beneficial effects in animal models of sepsis. After successful experimental studies, 
several randomized double-blind placebo-controlled trials were carried out to modify 
inflammatory response by specific anti-inflammatory agents in clinical sepsis (Marshall 
2000). These included studies of administering monoclonal antibodies against 
endotoxin, interleukin-1 receptor antagonist (IL-1ra), monoclonal antibodies against 
TNF-Į and soluble TNF-Į receptors. Despite encouraging results in the experimental 
and preliminary clinical trials, the large phase III trials could not confirm beneficial 
effects on patient outcome (Table 4). 
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Table 4. Randomized, placebo controlled phase III immunomodulatory trials in severe sepsis and septic 
shock. 
 
Therapy  
Number of 
patients 
28-day mortality 
placebo group 
28-day mortality  
treatment group 
Absolute risk reduction 
(95% CI) 
Antiendotoxin therapy    
Ziegler 1991 531 43% 39% - 4% (-12% - +5%) 
McCloskey 1994 2199 36% 38% + 3% (-1% - +7%) 
     
IL -1 receptor antagonist therapy    
Fisher 1994 893 34% 30% - 4% (-8% - +1%) 
Opal 1997 696 41% 39% - 2% (-9% - +5%) 
   
Soluble TNF-receptor fusion protein therapy   
Abraham 1997 498 39% 35% - 4% (-14% - +6%) 
Abraham 2001 1342 28% 27% - 1% (-6% - +4%) 
    
Monoclonal TNF-antibody treatment    
Abraham 1998  1878 43% 40% - 3% (-7% - +2%) 
Reinhart 2001 944 58% 54% - 4% (-13% - +6%) 
Panacek 2004 998 48% 44% -4% (-10% -+2%) 
CI: confidence interval. 
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A common feature in these trials was that anti-inflammatory treatments usually 
demonstrated marginally beneficial effects on survival, but this difference did not reach 
the statistical significance (Marshall 2000). A retrospective subgroup analysis in the 
first phase III clinical trial of IL-1ra suggested that the treatment with IL-1ra caused a 
dose-related increase in survival among patients with highest risk of death (Fisher 
1994). The second phase III trial, however, could not confirm these beneficial findings, 
and the study was terminated after an interim analysis found that it was unlikely that the 
primary efficacy endpoints would be met (Opal 1997). Studies which aimed to TNF 
neutralization generally showed small nonsignificant survival benefit in the treatment 
group and a pooled data revealed 3.5% reduction in mortality (Marshall 2000). A 
striking exception was obtained in a phase II clinical trial using a TNF inhibitor, in 
which a significant dose-related increase in mortality was observed in those patients 
who received TNFR:Fc therapy (Fisher 1996). 
 
Proinflammatory cytokines are considered to have a major cytotoxic effect in sepsis, but 
they also have beneficial effects. An adequate inflammatory response is needed to cope 
with an infectious insult, and a complete blocking of the inflammatory cascade is 
detrimental (Opal 1996). Proinflammatory cytokines are involved in the immunological 
response devoted to the elimination of the invading organism. In experimental studies, 
there are several reports in which worsening of an infection has been demonstrated by 
the complete blocking the actions of TNF (Grau 1997). Blocking the actions of one key 
cytokine disturbs the balance between proinflammatory and anti-inflammatory 
response. An ideal immunomodulatory treatment should be able to block the toxic 
effects of cytokines while preserving the beneficial effects. Failure of the 
immunomodulatory trials may be due to fact that patients with sepsis represent a very 
heterogeneous group of patients (Marshall 2000). It has been suggested that the 
immunomodulatory therapies could be beneficial in a subgroup of patients who have an 
apparent hyperinflammatory response during sepsis (Reinhart 1996, Reinhart and 
Karzai 2001). For example, in the MONARCS trial monoclonal antibodies to TNF-Į 
seemed to reduce mortality in the subgroup of patients with IL-6 levels above 1000 
pg/ml (Panacek 2004). 
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2.4 Compensatory anti-inflammatory response 
 
Compensatory anti-inflammatory response in clinical sepsis 
 
After the negative results obtained from immunomodulatory trials, it has become 
evident that sepsis-triggered immunological cascades are bidirectional. In addition to 
the systemic inflammatory response, the compensatory anti-inflammatory response 
(CARS) is also activated in sepsis (Bone 1996). The early proinflammatory period is 
progressively suppressed by the development of the anti-inflammatory response, which 
probably has an important down-regulating role of various inflammatory reactions. To 
ensure that the effects of proinflammatory mediators do not become destructive, the 
body launches anti-inflammatory substances, including IL-4, IL-10, IL-11, IL-13, 
soluble tumor necrosis factor receptors, interleukin-1 receptor antagonists and 
transforming growth factors (Bone 1996, Opal 2000). Theoretically, these anti-
inflammatory substances may have an important regulatory function in controlling and 
attenuating the systemic inflammatory response in sepsis, but the exact the role of the 
compensatory anti-inflammatory response is not completely understood (Goldie 1995, 
Bone 1996).  
 
Endogenous IL-10 production may represent an important regulatory mechanism in 
CARS, which controls the intensity of the inflammatory reactions. In experimental 
gram-negative sepsis, IL-10 production has shown to have an important protective 
function (Goldman 1996). Similar favourable effects of IL-10 production were observed 
in gram-positive sepsis (Floriquin 1994). In an animal model of septic peritonitis IL-10 
has prevented lethal complications and several clinical reports suggest that endogenous 
IL-10 production may have important protective effects in ARDS, acute pancreatitis and 
in SIRS (van der Poll 1995, Donelly 1996, Armstrong 1997, Simovic 1999, Taniguchi 
1999). 
 
In certain circumstances, the anti-inflammatory response may also have detrimental 
immunosuppressive effects. First evidence of exaggerated immunosuppression in sepsis 
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was obtained as early as in 1977, when Meakins and coworkers demonstrated a loss of 
delayed hypersensitivity as a marker of anergy (Meakins 1977). Later Ertel et al. 
demonstrated that lipopolysaccharide-stimulated whole blood from patients with sepsis 
released markedly smaller quantities of the proinflammatory cytokines than blood from 
control patients (Ertel 1995). Other features which indicate excessive 
immunosuppression include defects in antigen presentation (Oberholzer 2001), 
decreased macrophage activation (Hotchkiss 2003), defective T-cell proliferation 
(Heidecke 1999), decreased monocyte HLA-DR expression (Kox 2000, Keh 2003, 
Hynninen 2003) and increased T-cell and B-cell apoptosis (Hotchkiss 2001). The 
disproportionate release of anti-inflammatory mediators may manifest clinically as an 
increased susceptibility to nosocomial infections (O'Sullivan 1995).
 
Excessive production of IL-10 may mediate detrimental immunosuppressive actions in 
sepsis (Perl 2006). Although other studies have documented beneficial effects 
associated with adequate IL-10 production, there are studies where highest IL-10 levels 
have been observed among the nonsurvivors, and it has been proposed that the sustained 
overproduction of IL-10 is the major predictor of poor outcome in sepsis (van Dissel 
1998, Gogos 2000). The relationship between the proinflammatory and anti-
inflammatory cytokine responses in sepsis is inconsistent and varies between the 
studies. The conflicting results can be explained by the differences in the study 
populations and the short half-life of cytokines in the circulation. In clinical sepsis 
tissue concentrations of cytokines can be significant, but the plasma concentrations may 
be extremely low due to rapid elimination from circulation (Hack 1997). 
 
Modulation of SIRS / CARS balance 
 
Genetic factors modify both intensity and nature of the individual inflammatory 
response (Westendorp 1997). Genetic predisposition alters inflammatory response 
because genomic polymorphisms influence to the capacity of immune cells to produce 
cytokines. Multiple genomic polymorphisms within the genes encoding 
proinflammatory and anti-inflammatory cytokines, as well as cytokine receptor 
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antagonists have been identified (Holmes 2003). Genetic factors have been shown to 
have a significant impact on TNF-Į production and monocytes of healthy individuals 
show large differences in TNF-Į production after standardized stimulation (Jacob 
1991). In clinical studies, TNF-Į genomic polymorphism have been found to influence 
patient outcome in severe sepsis and certain alleles have been associated with 
significantly elevated TNF-Į levels, development of multiple organ failure and 
increased mortality (Stuber 1996, Nadel 1996). Polymorphisms within anti-
inflammatory cytokine genes have also been reported to have an impact on cytokine 
production (Schaaf 2003). 
 
An elementary feature in the modulation of the individual immune response is the 
functional diversity of T helper lymphocytes (Abbas 1996). CD4+ T-helper (Th) 
lymphocytes can differentiate into functionally two different subsets of Th cells 
depending on the microenvironment of the cell. Precursor T helper (Th0) cells can 
develop either to Th1 or Th2 cells, which produce distinct patterns of cytokines 
(Mossman 1996). Thl cells secrete interleukin-2 (IL-2) and interferon-Ȗ (IFN-Ȗ), thus 
creating a proinflammatory response, whereas Th2 cells produce anti-inflammatory 
response by secreting IL-4, IL-5, IL-6, IL-10, and IL-13 (Mosmann 1996).  
 
In sepsis, site and type of infection modulate Th1/Th2 balance and local cytokine 
concentrations have substantial influence on T cell differentiation (van Deventer 2000). 
IL-4, IL-10 and IFN-Ȗ are considered to be central cytokines that modulate this balance 
(Mosmann 1996, Abbas 1996). Both IL-10 and IFN-Ȗ cross-regulate T cell 
differentiation. IFN-Ȗ produced by Th1 cells amplifies the growth of Th1 cells and 
inhibits proliferation of Th2 cells, whereas IL-10 produced by Th2 cells blocks the 
activation of Th1 cells (Sher 1991, Asadullah 2003). IL-10 and IFN-Ȗ induce self-
amplification in Th cell maturation and once immune response begins to develop along 
one pathway, it becomes progressively polarized in that direction (Abbas 1996). The 
Th1/Th2 balance may be disturbed in severe sepsis, and in flow cytometry analysis 
alterations in T helper cell subset favouring Th2 response have been detected (Ferguson 
1999). In addition to IL-10, IL-4 and IFN-Ȗ, endogenous cortisol production modulates 
Th1/Th2 response in individual patients (Gonzalez 2006).  
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2.5. Hormonal regulation of the inflammatory process 
 
Hypothalamic-pituitary adrenal activation in sepsis 
 
Activation of the immune system in critical illness is accompanied by endocrinological 
alterations to provide optimal conditions to cope with acute stress. In the clinical setting 
neuroendocrine and immune system are linked together, and especially the activation of 
the hypothalamic-pituitary-adrenal (HPA) axis has significant effect on immune-
mediated inflammatory reactions (Chrousos 1995). Although immunosuppressive 
effects of cortisol have been known for decades, it has only recently become apparent 
that immuno-neuroendocrine interactions are bidirectional (Beihuizen 2004).  
 
In severe sepsis and septic shock serum cortisol levels are substantially elevated (Schein 
1990). This activation of HPA axis and subsequent increase in cortisol production is 
considered to be essential for survival (Melby 1958, Finlay 1982, Rothwell 1991). 
Cortisol has a vital role in the maintenance of vascular tone, endothelial integrity, 
vascular permeability and the distribution of total body water within the vascular 
compartments (Lamberts 1997, Zaloga 2001). Adequate cortisol production has a 
crucial role in the maintenance of cardiovascular homeostasis during acute stress. In 
experimental sepsis adrenalectomy leads to fatal circulatory collapse, which can be 
prevented by replacement of corticosteroids (Hinshaw 1985).  
 
Further evidence for the vital role of intact adrenal activity in critical illness was 
obtained by the etomidate-induced hypocortisolism. Etomidate blocks cortisol synthesis 
by inhibiting 11-ȕ-hydroxylase activity. In 1979-1982 ICU mortality among trauma 
patients increased from 25% to 44% when etomidate was used as an anaesthetic agent in 
critical care units (Ledingham 1983). Later the inhibitory effects of etomidate were 
confirmed in a randomized prospective trial (Absalom 1999). In prolonged septic shock 
reduced adrenoreceptor sensitivity to vasopressors may be restored by corticosteroids, 
and cortisol can potentiate the vasoconstrictive action of catecholamines by increasing 
beta-adrenergic receptor synthesis and density (Saito 1995, Saito 1996, Annane 1998). 
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Glucocorticoids have potent anti-inflammatory and immunomodulatory effects. Cortisol 
inhibits transcription of the genes encoding pro-inflammatory cytokines by reducing 
nuclear factor kappa (NF-țB) activity (Auphan 1995). As a result, corticosteroids block 
the synthesis or the action of most pro-inflammatory cytokines (IL-1ȕ IL-2, 1L-3, IL-6, 
IFN-Ȗ and TNF-Į) (Auphan 1995, Zuckerman 1989). Although the majority of the anti-
inflammatory effects of corticosteroids are due to direct suppression of proinflammatory 
cytokine synthesis, part of the effects are due to the enhanced production of anti-
inflammatory cytokines, like IL-10 (Tabardel 1996). Glucocorticoids induce a shift 
from a proinflammatory Th1 response to a Th2 response, which enhances the 
production of IL-4, IL-10 and IL-13 (Ramirez 1996). Glucocorticoids limit 
inflammatory reactions by decreasing expression of adhesion molecules, suppressing 
the release of proteolytic enzymes and inhibiting cyclo-oxygenase and inducible nitric 
oxide synthase activity (Di Rosa 1990, Cronstein 1992). The inhibition of nitric oxide 
synthase and cylo-oxygenase-2 activity not only down-regulate inflammatory reactions, 
but they also exert positive effects on hemodynamics by limiting the production of 
vasodilatory and procoagulant factors (Keh 2003). The main physiological actions of 
glucocorticoids in septic shock are presented in Table 5. 
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Table 5. Main effects of glucocorticoids in septic shock. 
 
Cardiovascular effects 
 Maintenance of vascular tone  
 Regulation of vascular permeability 
 Increase vascular sensitivity to catecholamines 
Regulation of sodium and potassium excretion 
 Regulation of water excretion 
 Increase beta adrenergic receptor synthesis and affinity 
  
Anti-inflammatory effects 
 Reduction in the proinflammatory cytokine production (TNF, IL-1ȕ, IL-6) 
 Increase in the anti-inflammatory cytokine synthesis (IL-10, IL-1ra) 
 Decrease in the adhesion molecule expression 
 Inhibition of chemokine (IL-8) synthesis  
 Inhibition of soluble phospholipase-A2 synthesis 
 Inhibition of inducible cyclooxygenase-2 synthesis 
 Inhibition of inducible nitric oxide synthase synthesis 
 
Metabolic effects 
 Stimulation of gluconeogenesis 
 Inhibition of peripheral tissue glucose uptake 
 Stimulation of hepatic glycogenolysis 
 Activation of lipolysis 
 Exacerbation of insulin resistance 
 
 
The conventional activation of the cortisol production occurs via corticotropin releasing 
hormone (CRH) – adrenocorticotropic hormone (ACTH) –activation. Hypothalamic 
CRH activates the pituitary release of ACTH, which in turn stimulates cortisol and 
dehydroepiandrosterone secretion in adrenal cortex (Feek 1983). Secretion of CRH is 
pulsatile and is followed by the pulsatile release of ACTH (Voerman 1992). The central 
sympathetic nervous system stimulates hypothalamus to secrete CRH. The adrenal 
glands also receive a direct sympathetic nerve supply, and the activation of the 
sympathetic nervous system activates also directly cortisol production (Stewart 2003). 
In addition to CRH, hypothalamic vasopressin (AVP) stimulates ACTH secretion. In 
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normal conditions AVP alone has a minor effect on ACTH secretion, but it acts 
synergistically with CRH (Chrousos 1995).  In healthy subjects cortisol production is 
regulated by a negative feedback mechanism exerted by secreted cortisol on CRH and 
ACTH synthesis (Feek 1983). Figure 1 demonstrates the normal physiological 
activation of the HPA-axis. 
 
 
 
 
 
 
 
 
Figure 1. Normal activation of the hypothalamic-pituitary-adrenal axis. Continuous arrows indicate 
activation, broken arrows indicate inhibitory effects. AVP: vasopressin; CRH: corticotropin-releasing 
hormone; ACTH: adrenocorticotropic hormone. 
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In sepsis and septic shock, significant functional alterations occur in the HPA axis. 
Typically, a biphasic pattern of HPA activation is observed (Beishuizen 2004). In the 
acute phase high cortisol concentrations are associated with elevated ACTH levels, 
which reflect normal physiological activation (Bornstein 1998). In the second phase, a 
discrepancy between high cortisol levels and low ACTH levels is observed (Vadas 
1988, Vermes 1995). In this chronic or prolonged phase of critical illness non-ACTH 
mediated pathways become major regulators of cortisol production. The inflammatory 
cytokines, TNF-Į, IL-1, IL-2 and IL-6 can activate the hypothalamic-pituitary-adrenal 
axis independently, and in combination they have a synergistic effect (Darling 1989, 
Imura 1991, Mastorakos 1993, Chrousos 1995). These cytokines exert their effects on 
cortisol production by increasing CRH and ACTH release but they also have direct 
effects on adrenal glands. Especially IL-6 is a powerful stimulator in the non-ACTH 
mediated activation of the adrenal function during critical illness (Mastorakos 1993, 
Soni 1995). In addition, IL-10 and its receptors are produced in pituitary and 
hypothalamic tissues, and IL-10 has been shown to enhance CRH and ACTH 
production in hypothalamus and pituitary gland (Rady 1995, Smith 1999). In normal 
subjects cortisol secretion follows a circadian pattern, but in critical illness these 
circadian changes are typically diminished or even lost (Voerman 1992, Schuetz 2006). 
 
In addition to cytokines, vasoactive peptides activates HPA axis in sepsis. Vasopressin-
mediated activation of V3 receptors in the hypophysis facilitates the release of ACTH 
(Feek 1983, Chrousos 1995). Other vasoactive peptides, such as endothelin, atrial 
natriuretic peptides and pro-adrenomedullin, are all capable of modulating 
adrenocortical function, but the exact role of these substances in the activation of the 
HPA axis is not fully established (Vermes 1995, Chirst-Crain 2005).  
 
Another cause for the elevation of cortisol in critical illness is a shift from adrenal 
androgen and mineralocorticoid production towards glucocorticoid biosynthesis 
(Vermes 2001). In normal situations, dehydroepiandrosterone (DHEA) and 
dehydroepiandrosterone sulfate (DHEAS) are most abundantly secreted steroids by the 
adrenal cortex, but in critically ill patients especially the serum levels of DHEAS levels 
are significantly decreased while cortisol levels are elevated  (Beishuizen 2002). 
 39
DHEA/DHEAS are potent proinflammatory modulators of the immune response 
(Beishuizen 2004). DHEA stimulates the Th1-cell function, and the increase in cortisol 
production and concomitant decrease in DHEA/DHEAS synthesis may aggravate 
immunosuppression in sepsis (Schuetz 2006).  
 
The metabolism of cortisol is changed in sepsis. The half-life of cortisol is increased 
during septic shock (Melby 1958). This increase of half-life is due to decreased rate of 
hepatic extraction and decreased renal enzymatic inactivation.  This is explained by the 
changes in the 11ȕ-hydroxysteroid dehydrogenase type I and type II activities, which 
modulate the cortisol/cortisone balance (Venkatesh 2007). In critical illness, cortisol 
binding globulin levels show remarkable changes and extremely low CBG levels have 
been observed in patients with septic shock (Beishuizen 2001). Since cortisol is bound 
to a large extent to CBG, and only the free hormone is considered to be biologically 
active, changes in CBG concentration affects the bioavailability of cortisol (Stewart 
2003). 
 
 
Relative adrenal insufficiency in sepsis  
 
Although cortisol production is usually enhanced in sepsis, some patients may have 
relative or functional adrenocortical dysfunction, a concept introduced by Schein and 
Rothwell (Schein 1990, Rothwell 1991). Relative adrenal insufficiency is characterized 
by situations where measured cortisol levels are normal or even elevated, but they are 
still considered to be inadequate, and the patients may not be able to respond to any 
additional stress. In these situations cortisol demand is substantially increased, and 
therefore normal levels of cortisol may be inappropriate. Several approaches have been 
introduced to evaluate the adequacy of adrenal function in critically ill patients. Basal 
cortisol measurements, the low-dose (1 ȝg) ACTH test and the conventional (250 ȝg) 
ACTH test have been used in the assessment of cortisol production and adrenal reserve.  
 
The standard ACTH stimulation test is most commonly used method for identifying 
adrenocortical hyporesponsiveness in critically ill patients (Lamberts 1997). In the 
 40
standard test, a cortisol response to exogenous 250 ȝg ACTH is measured 30 and 60 
minutes intervals after corticotropin injection. Relative adrenal insufficiency is typically 
characterised by a supra-normal basal, but deficient post-stimulation increase in cortisol 
concentration.  
 
Rothwell at al. demonstrated that basal cortisol levels were identical in survivors and 
nonsurvivors in septic shock, but all nonsurviving patients demonstrated a poor cortisol 
increment (< 250 nmol/l) in the standard ACTH stimulation test (Rothwell 1991). Later 
in a large prospective study Annane et al. confirmed that this cortisol increment of 250 
nmol/l discriminated survivors and nonsurvivors well. Annane and coworkers 
developed a 3–level classification system of adrenal function based on the results of 
multivariate analysis (Annane 2000). The prognosis was good in those patients whose 
basal cortisol was below 937 nmol/l and the stimulation response was good (> 
250nmol/l); mortality in this group was 26%. In contrast, the prognosis was poorest in 
those patients who had high basal cortisol levels and a blunted ACTH response 
(baseline > 937 nmol/l and increment < 250 nmol/l) with a mortality rate of 82%. Other 
investigators have also demonstrated that a blunted adrenocortical response in ACTH 
test is associated with a poor prognosis in septic shock (Sibbald 1977, Soni 1995). 
However, not all studies confirm these findings and in a study by Bouachour et al. there 
was no correlation between cortisol response and mortality (Bouachour 1995).  
 
The standard ACTH stimulation test has been criticized to be insensitive in detecting 
clinically relevant changes in adrenal function. The standard ACTH stimulation test 
uses a corticotropin dose, that is 200-fold greater than ACTH levels produced during 
physiological stress (Marik 2000). It has been suggested that the low-dose (1Pg) ACTH 
stimulation test would be more sensitive in detecting adrenal insufficiency (Dickstein 
1991). In postoperative patients the low-dose test results were considered to be valid 
after uncomplicated surgery, but the test was more difficult to interpret in more severely 
ill postoperative patients (Richards 1999). In ICU patients the improved sensitivity of 
the low-dose ACTH test in detecting adrenal insufficiency has not been confirmed 
unambiguously (Soni 1995, Siraux 2005, Salgado 2006). 
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Random cortisol measurements have been suggested to replace the ACTH stimulation 
tests in the assessment of adrenal function. Marik performed both the high and low-dose 
test in 59 patients with septic shock to determine the sensitivity of each test in 
establishing a diagnosis of adrenal insufficiency (Marik 2003). In this study, a baseline 
cortisol concentration below 680 nmol/l predicted a beneficial clinical response to 
corticosteroids very accurately. In contrast, the sensitivity of the ACTH tests was poor. 
The conclusion in Marik´s study was that random cortisol measurements are more 
suitable than the ACTH stimulation tests in the assessment of adrenal function in septic 
shock patients. Table 6 summarizes the incidence of adrenal insufficiency in septic 
shock. 
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Table 6. Incidence of adrenal insufficiency (AI) in septic shock. 
 
Reference N ACTH test (μg) Criteria for AI (nmol/l) Incidence (%) 
 
Rothwell 1991 
 
32 250 increment < 250 41 
Moran 1994 68 250 increment < 200 peak level < 500 
 
67 
32 
 
Bouachour 1995 
 
40 
 
 
250 
 
increment < 250 
peak level < 500 
75 
6 
 
Soni 1995 
 
 
21 
 
 
1 
250  
 
 
peak level < 500 
peak level < 500 
 
29 
24 
 
 
Oppert 2000 20 250 increment < 200 55 
 
Annane 2000 189 250 increment < 250 54 
Bollaert 2003 82 250 
 
increment < 200 
increment < 250 
 
 
34 
38 
 
Marik 2003 59 
 
1 
249 
--- 
 
 
peak level < 500 
peak level < 500 
baseline < 680 
 
 
22 
8 
61 
 
 
Manglik 2003 100 250 peak level < 550 9 
Siraux 2005 
 
46 
 
1 
250 
 
increment < 250 
increment < 250 
 
67 
35 
 
Salgado 2006 
 
102 1 249 
 
 
increment < 250 
increment < 250 
 
54 
23 
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Etiology and risk factors of adrenal insufficiency 
 
Several mechanisms are involved in the development of relative adrenal insufficiency in 
septic shock. Insufficient blood flow to the adrenal cortex and specific substances that 
either inhibit ACTH secretion or directly depress adrenal function may induce adrenal 
failure. Necrosis or haemorrhage of the pituitary gland or adrenal cortex has been 
reported in sepsis as a result of prolonged hypotension or severe coagulopathy, but the 
destruction of the adrenal glands must be very extensive to produce cortisol 
insufficiency (Zaloga 2001). In most cases, autopsy findings of patients with 
documented adrenal insufficiency have revealed intact adrenal glands (Soni 1995, 
Annane 1998).  
 
Functional changes are probably more important determinants of adrenal insufficiency 
in sepsis. This concept is supported by findings in which impaired adrenal function 
during septic shock has normalized after recovery (Briegel 1996). In clinical sepsis 
cytokines stimulate HPA function, but also inhibitory effects are mediated by the 
cytokines. Especially local actions of TNF-Į are widely different depending on the site 
of action.  TNF-Į can activate the HPA axis via hypothalamic CRH or pituitary ACTH 
release, but in the adrenal cells TNF-Į  reduces the ability of adrenocortical cells to 
respond to ACTH stimulation (Jäättelä 1991, Chrousos 1995).  IL-6 is a very potent 
stimulus for both ACTH and cortisol secretion. Low IL-6 levels may contribute to 
adrenocortical insufficiency in sepsis because of understimulation of the pituitary-
adrenal axis (Soni 1995). Corticostatin, a peptide produced by immune cells, may also 
impair adrenocortical function by competing with ACTH trough binding to its receptor 
(Zhu 1992). 
 
Together with TNF-Į and IL-6, macrophage migration inhibitory factor (MIF) is a 
central cytokine that modulates adrenal function in sepsis (Baugh 2002). MIF is a potent 
proinflammatory cytokine that is released from macrophages and T lymphocytes that 
have been stimulated by glucocorticoids (Calandra 1995). MIF is able to antagonize the 
inhibitory effects of glucocorticoids on proinflammatory cytokine production, and it is 
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also able to overcome the glucocorticoid-induced inhibition of T-cell proliferation by 
restoring IL-2 and IFN-Ȗ production (Calandra 1997). MIF is produced by pituitary cells 
(Bernhagen 1993), and elevated MIF levels have been observed in adrenal glands 
(Baugh 2002). Since the main action of MIF is to counteract the effects of 
glucocorticoids, it is possible that MIF is a central cytokine in mediating bidirectional 
communication between the immune and neuroendocrine systems in sepsis (Beishuizen 
2001).  
 
Certain subgroups of septic shock patients may be at an increased risk for developing 
relative adrenal insufficiency. Especially patients who have received etomidate are at 
greater risk for developing adrenal failure. A prospective observational study by 
Malerba and coworkers demonstrated that a single dose of etomidate increased by 12 
times the risk of adrenal dysfunction (Malerba 2005). It has also been suggested that 
gender may have an influence on the development of adrenal insufficiency, but these 
results are conflicting. Malerba´s study proposed that relative adrenal insufficiency is 
more common in men, but a recent prospective study performed by Salgado et al. 
demonstrated that female sex was associated with a greater incidence of relative adrenal 
failure (Salgado 2008). Figure 2 presents the activation of the HPA axis during sepsis 
and septic shock. 
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Figure 2. HPA activation in sepsis. Continuous arrows indicate activation, broken arrows indicate 
inhibitory effects. AVP: vasopressin; ACTH: adrenocorticotropic hormone; CRH: corticotropin-releasing 
hormone; MIF: macrophage migration inhibitory factor. 
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2.6. Therapeutic aspects 
 
 
High-dose corticosteroids in severe sepsis and septic shock 
 
In theory, glucocorticoids have numerous beneficial effects in the treatment of severe 
sepsis. In a relatively small study performed by Schumer demonstrated that treatment 
with dexamethasone or methylprednisolone improved patients’ survival in severe sepsis 
(Schumer 1976). As a result, large well-designed randomised controlled studies were 
performed to find out whether the corticosteroid treatment has any benefit in the 
treatment of severe sepsis or septic shock (Sprung 1984, Bone 1987, VASSCS 1987, 
Luce 1988). In these studies patients received extremely high-dose corticosteroid 
treatment (up to 42 000 mg of hydrocortisone equivivalent) in the early phase of sepsis 
(Lefering 1995). The treatment period was extremely short and typically patients 
received one, two or four dosages of corticosteroids within the first 24 hours. None of 
these studies could demonstrate any beneficial effects on shock reversal or mortality. In 
all studies corticosteroid treatment was either not useful (VASSCS 1987) or even 
harmful (Sprung 1984, Bone 1987, Luce 1988). These results were later confirmed in 
several meta-analyses, which concluded was that high-dose corticosteroids should not 
be used in the treatment of severe sepsis or septic shock (Lefering 1995, Cronin 1995, 
Annane 2004).  In general, it was assumed that high doses of glucocorticoids failed to 
dampen the overactive inflammatory response, but instead induced immunosuppression 
(Keh 2006). 
 
 
Low-dose hydrocortisone therapy in septic shock 
 
A renewed interest of corticosteroid therapy in septic shock occurred in 1990´s due to 
an increased understanding of functional adrenal insufficiency. The concept that relative 
adrenal dysfunction is associated with poor prognosis in sepsis led to the studies where 
the effects of low-dose hydrocortisone treatment were investigated in vasopressor-
dependent septic shock. The hypothesis was that considerably lower replacement doses 
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of hydrocortisone in prolonged therapy could restore homeostasis, increase vasomotor 
tone, and have positive anti-inflammatory effects without causing exaggerated 
immunosuppression.  
 
The first prospective double-blind study that evaluated low-dose glucocorticoids in the 
treatment of septic shock involved 41 patients from two intensive care units in France 
(Bollaert 1998). Patients received either hydrocortisone treatment (100 mg three times 
daily during 5-day period), or placebo, tapered over 6 days. In this study, it was 
calculated that a sample size of 80 patients would be needed to detect a 30% difference 
in the rate of shock reversal. However, in an interim analysis the results showed a 
striking difference in shock reversal between the study groups, and the study was 
discontinued after 41 patients. Shock reversal by day 7 was achieved in 68% of the 
treatment group versus 21% of the placebo group (p=0.007). There was also a trend 
towards lower 28-day mortality in the treatment group, but due to the small sample size 
this did not reach the statistical significance. In a second double-blind single-center 
study from Germany, 40 patients with septic shock were randomized to receive 
hydrocortisone by continuous infusion of 0.18 mg/kg/h or placebo and when shock was 
reversed, the hydrocortisone dosage was reduced to 0.08 mg/kg/h for 6 days (Briegel 
1999). The primary end point was the time until shock reversal as defined by cessation 
of alpha-adrenergic support. In this study, it was calculated that a sample size of 40 
patients was necessary to detect a 45% difference in shock reversal 48 hrs after starting 
treatment. This study showed a significant hemodynamic improvement in the treatment 
group as well. The time to reversal of shock vas achieved at a median of 2 days in the 
hydrocortisone group, and in 7 days in the placebo group (p=0.005). The overall 
mortality was not affected by the treatment (Briegel 1999). In both studies 
hydrocortisone treatment was well tolerated, and no serious adverse events were 
observed. Later Keh and co-workers confirmed these findings in a crossover study 
where hydrocortisone therapy shoved a clear effect on shock reversal (Keh 2003). Keh´s 
study demonstrated that hydrocortisone treatment increased blood pressure and systemic 
vascular resistance and decreased heart rate, cardiac index, and catecholamine 
requirement.  
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In addition to hemodynamic effects, Keh investigated immunological mechanisms 
underlying the beneficial effects of low-dose hydrocortisone therapy. Hydrocortisone 
treatment significantly decreased the levels of both proinflammatory (IL-6 and IL-8) 
and anti-inflammatory cytokines (IL-10 and soluble TNF-Į receptors), whereas the 
monocyte-activating cytokine interleukin-12 levels were increased (Keh 2003). In vitro 
granulocyte function remained intact, indicating that low-dose hydrocortisone did not 
suppress innate defence mechanisms. The treatment thus modulated the immunologic 
response towards anti-inflammation rather than towards immunosuppression. Similar 
balancing effects on the immune response have also been reported by other 
investigators. Briegel and Oppert demonstrated decreased IL-6 and IL-8 levels, whereas 
IL-10 levels were unaltered (Briegel 2001, Oppert 2005). These findings suggest that 
hydrocortisone treatment may correct the imbalance between overactive 
proinflammatory response and inadequate anti-inflammatory response, and it may 
improve innate immunity in the early stage of septic shock. In contrast to high-dose 
methylprednisolone treatment which was believed to induce immunosuppression, the 
low-dose hydrocortisone therapy may actually have an immunobalancing and 
immunoenhancing role in sepsis (Briegel 2001, Bornstein 2003, Kaufmann 2007).  
 
After Briegel´s and Bollaert´s trials, a relatively large multicenter study conducted in 
France was published in 2002 by Annane and co-workers (Annane 2002). This double-
blind randomized study of 299 patients from 19 intensive care units investigated the 
effects of corticosteroid therapy in refractory septic shock. The treatment group received 
intravenous hydrocortisone 50 mg every 6 hours and fludrocortisone 50 ȝg every 24 
hours for 7 days. The therapy was started within 8 hours of the onset of septic shock. Of 
the 299 patients, 229 were nonresponders in the ACTH test and only 70 were 
considered to have normal adrenal function.  In this trial, the steroid replacement 
therapy showed a significant reduction in mortality in those patients who had adrenal 
insufficiency. In contrast, patients with normal adrenal function did not seem to benefit 
from the treatment. Also shock reversal was significantly enhanced only in those 
patients who had a poor response in the ACTH stimulation test, whereas in patients with 
normal ACTH response no beneficial effect was observed. The authors suggested that 
hydrocortisone-fludrocortisone combination treatment should be given to all patients 
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with refractory septic shock after the ACTH stimulation test, and when the tests results 
are available the treatment should be discontinued to those patients whose adrenal 
function was normal. 
 
Annane´s study faced considerable criticism in medical journals. Among the ACTH 
nonresponders, 28-day mortality was 63% in the placebo group and 53% in the 
treatment group. This reduction in mortality was statistically significant only after 
complex statistical maneuvers when the results were adjusted for baseline cortisol 
levels, cortisol response, McCabe classification, organ dysfunction score, arterial lactate 
levels and PaO2/FiO2 ratios using logistic models. In a conventional nonparametric test, 
however, a statistically significant reduction in mortality was not observed (p=0.096 
Chi-square test between groups). In addition, 72 patients received etomidate within 24 
hours after the randomization, and 68 of these patients (94%) developed adrenal 
insufficiency (Annane 2003). This drug-induced adrenal failure may have had a 
substantial influence on the results. The possible beneficial role of fludrocortisone in 
this therapy needs to be also further studied in detail. 
 
 
Coagulation inhibitors in sepsis 
 
In sepsis, inflammatory and procoagulant host responses to infection are closely related. 
Release of proinflammatory cytokines initiates not only the activation of the systemic 
inflammatory response, but it also activates coagulation pathways (Esmon 1999). 
Proinflammatory cytokines TNF-Į and IL-6 activate coagulation by stimulating the 
release of tissue factor from monocytes and endothelium, which leads to the increased 
conversion of prothrombin to thrombin (Levi 2002). Concomitantly, natural 
anticoagulant and fibrinolytic activity are impaired (Levi 1999). Intravascular thrombin 
generation is considered to be a highly inflammatory stimulus and enhanced coagulation 
and inflammation are thought to from a vicious cycle in the pathophysiology of sepsis 
(Esmon 2001). 
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The pharmacological modification of the coagulation system has been an important 
target for treatment of sepsis because natural anticoagulant systems also have anti-
inflammatory effects. In normal conditions, thrombin generation is limited by the tissue 
pathway inhibitor, antithrombin and the protein C system (Levi 1999). During severe 
sepsis, all three regulatory systems are defective as a result of endothelial dysfunction 
(Levi 2002). All of these systems have anti-inflammatory effects and also modulate 
intracellular signaling, cytokine secretion, cellular apoptosis and leukocyte-endothelial 
interactions. Numerous experimental and clinical studies have investigated whether 
these natural coagulation inhibitors could improve patient outcome in severe sepsis due 
to their anticoagulant and anti-inflammatory effects. Recombinant tissue factor pathway 
inhibitor (TFPI) and antithrombin seemed to improve patient prognosis in sepsis in 
experimental and phase 2 clinical studies (Eisele 1998, Abraham 2001), but in phase 3 
studies these positive results could not be confirmed.  TFPI has been evaluated in a 
large phase 3 clinical trial (OPTIMIST), which involved 1,987 patients. This trial found 
no substantial improvement in 28-day survival even a subgroup of patients not receiving 
concomitant heparin seemed to benefit from the treatment (Abraham 2003). Similar 
findings were observed in large antithrombin trial, which involved 2,314 septic patients 
(Warren 2001).  
 
In 2001, recombinant human activated protein C (rhAPC) was approved for the 
treatment of severe sepsis after the results obtained in a prospective PROWESS study. 
In this randomized, controlled phase III clinical trial, 1,690 patients with severe sepsis 
were randomized to receive either a continuous infusion of APC (24 μg/kg/h) for 4 
days, or placebo (Bernard 2001). Administration of rhAPC caused a significant 
reduction in 28-day mortality. The mortality rates of those patients randomized to APC 
was 24.7%, while patients receiving placebo had mortality rate of 30.8%. Treatment 
with rhAPC was associated with a 19.4% relative reduction in mortality (p = 0.0049). 
APC also reduced D-dimer and IL-6 plasma levels, suggesting diminished activation of 
the coagulation pathway and reduced cytokine production (Bernard 2001). A post hoc 
subgroup analysis revealed that the treatment effect was only evident in the most 
severely ill patients with a higher risk of death, defined by an APACHE II score > 25 
(Angus 2004). 
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After positive results obtained from the PROWESS trial, subsequent studies have not 
confirmed similar beneficial effects in other study populations, such as children or 
adults with lower severity of illness (Abraham 2005, Eisenberg 2005). A prospective 
ADDRESS trial was carried out in septic patients with lower risk of death in order to 
clarify the efficacy and safety of rhAPC in this specific population (Abraham 2005). For 
the primary end-point in the ADDRESS study, 28-day mortality, no difference between 
treatment and placebo group was observed.  The mortality rate in the placebo group was 
17% and in the treatment group 18.5%. Furthermore, 321 patients in the ADDRESS 
study had APACHE II scores > 25 at the enrolment, and in this patient population the 
mortality rates in the rhAPC group was 29.5% and 24.7% in the control group. The 
pediatric sepsis rhAPC study was discontinued prematurely because lack of efficacy 
(Eisenberg 2005). These conflicting results concerning the use of rhAPC have created 
substantial controversy regarding efficacy, safety and cost-benefit profile of APC in the 
treatment of sepsis (Costa 2007). It has been suggested that the risks of rhAPC therapy 
may outweigh its benefits (Dellinger 2006, Mackenzie 2006, Eichacker 2007). 
 
 
Intensive insulin therapy 
 
Intensive insulin therapy and strict normoglycemia has been shown to reduce morbidity 
and mortality among critically ill surgical patients (Van den Berghe 2001). Intensive 
insulin therapy exerts anti-inflammatory effects and tight glycemic control has been 
reported to prevent excessive inflammation as illustrated by lower C-reactive protein 
and mannose-binding lectin levels (Hansen 2003). Persistently elevated blood glucose 
levels may be harmful due to intrinsic proinflammatory effects of hyperglycemia, which 
may aggravate systemic inflammatory response (Yu 2003). In addition, insulin itself has 
potent anti-inflammatory properties (Marik 2004). Although intensive insulin therapy 
has shown to reduce mortality in critically ill surgical patients, there in no clinical study 
that has confirmed these beneficial effects in sepsis. A recent prospective randomized 
study performed in Germany in patients with severe sepsis was discontinued 
prematurely because of identical mortality rate in the intensive insulin and control 
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group, and a greater incidence of hypoglycemia in the tight blood sugar group 
(Brunkhorst 2008).  
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3. AIMS OF THE STUDY 
 
 
The objective of the present study was to evaluate the clinical significance of the 
compensatory anti-inflammatory response in severe sepsis and septic shock. The 
specific objectives were: 
 
1. To investigate the role of adrenal insufficiency in the development and 
resolution of multiple organ failure (Study I). 
 
2. To study the role of the anti-inflammatory cytokine response in the pathogenesis 
of multiple organ failure (Study II). 
 
3. To investigate the dynamic changes in adrenocortical function in critically ill 
patients and to assess the reproducibility of the ACTH test in patients with or 
without sepsis (Study III). 
 
4. To study the effects of hydrocortisone therapy on glycemic control and 
hemodynamic changes in septic shock (Study IV). 
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4. PATIENTS AND METHODS 
 
4.1. Patients 
 
Patient characteristics 
 
One-hundred-seventy-three critically ill patients were enrolled in the study. Of these, 
120 had septic shock and 33 severe sepsis. In addition, 20 nonseptic critically ill 
patients in study III served as a control group. Studies I and II were performed in the 
Surgical Intensive Care Unit of Tampere University Hospital and studies III and IV 
were multicenter studies conducted in the Intensive Care Units of Tampere University 
Hospital, Kuopio University Hospital, Päijät-Häme Central Hospital and South-Carelian 
Central Hospital. Fourteen patients from the study I also participated in study II. 
 
Sepsis was defined according to the American College of Chest Physicians / Society of 
Critical Care Medicine Consensus Conference as the presence of systemic inflammatory 
response syndrome and a documented source of infection (Bone 1992). In studies I and 
II severe sepsis was defined as a sepsis associated with organ dysfunction, 
hypoperfusion abnormality or sepsis-induced hypotension (Bone 1992). The criteria for 
organ dysfunction and hypoperfusion abnormality were defined as the presence of one 
or more of the following manifestations: hypoxemia (PaO2 < 10 kPa), elevated plasma 
lactate level (> 2 mmol/l), or oliguria (urine output < 30 ml/h) (Bone 1987). Septic 
shock was defined as a sepsis associated with hypotension despite adequate fluid 
resuscitation (systolic blood pressure < 90 mmHg or a decrease of systolic blood 
pressure by 40 mmHg or more from the baseline) (Bone 1992).  The patient data are 
summarized in the Table 7. 
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Table 7. Demographics of the patients at ICU admission. 
 
 Study I Study II Study III Study IV 
Inclusion criteria severe sepsis severe sepsis ICU patients septic shock 
No of patients 41 38 60 48 
Age 53.0 ± 15.8 52.8 ± 14.4 56.9 ± 13.3 60.6 ± 16.6 
APACHE II 13.5  ± 5.7 13.3 ± 5.8 20.4 ± 6.3 22.6 ± 6.8 
SAPS II 34.5 ± 12.2 32.9 ± 10.4 44.1 ± 12.2 51.9 ± 12.9 
SOFA score 8.5 ± 2.8 8.4 ± 2.9 8.5 ± 2.9 10.2 ± 2.3 
ICU mortality 31.7% 31.6% 20% 22.9% 
 
 
 
 
Exclusion criteria 
 
Patients under 18 years of age and patients receiving glucocorticoids were excluded 
from the study. Patients who died within 24 hours of the onset of sepsis were also 
excluded (two in the study I, one in the study II and three in the study IV). In study I, 
one patient was excluded because of absolute adrenocortical insufficiency (stimulated 
cortisol level < 500 nmol/l). In study IV, pre-existing diabetes was an additional 
exclusion criterion. 
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4.2. Methods 
 
Study designs 
 
   Study I. Study I was a prospective observational study. The purpose of the study was 
to investigate the incidence of adrenal insufficiency in severe sepsis and its relation to 
the development and resolution of multiple organ failure. In all, 41 patients who 
fulfilled the criteria of severe sepsis or septic shock were enrolled in the study. A short 
ACTH stimulation test was performed within 24 hours of the diagnosis of severe sepsis. 
A peak cortisol level < 680 nmol/l and a rise in serum cortisol level less than 260 nmol/l 
were used as the criteria for relative adrenocortical insufficiency (Seppälä 1996). After 
the ACTH test the serum cortisol values were followed on the third and fifth day of the 
intensive care (ICU) period. The severity of organ dysfunction was assessed daily using 
the Sequential Organ Failure Assessment (SOFA) score (Vincent 1996). At the time of 
ACTH test, plasma ACTH measurements were also performed. Length of ICU stay, 
duration of mechanical ventilation, ICU mortality and hospital mortality rates were 
assessed in study I. 
 
   Study II. Study II was a prospective observational study that investigated the 
relationship between the pro- and anti-inflammatory cytokine response in severe sepsis 
and their role in the development of multiple organ failure (MOF). Thirty-eight patients 
who fulfilled the criteria of severe sepsis were prospectively enrolled in the study. Serial 
cytokine analyses were performed in two separate study groups: one in patients who 
developed severe multiple organ dysfunction and the other with no evidence of severe 
organ dysfunction. The severity of organ dysfunction was assessed daily by the SOFA-
scoring system. Severe multiple organ failure was defined prospectively as a maximum 
SOFA score of 10 or higher, which indicates severe dysfunction (grade 3 or 4) at least 
in three organ systems (Vincent 1998). Serial measurements of the plasma IL-6, IL-1ß, 
IL-10 and IL-1ra concentrations were performed. Cytokine samples were taken at the 
onset of severe sepsis followed by subsequent samples on the third and fifth day of the 
intensive care period. 
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   Study III. Study III was a multicenter prospective cohort study that included 60 
critically ill patients. In this study, the reproducibility of the ACTH stimulation test was 
investigated. Two consecutive short ACTH stimulation tests were performed in three 
separate study groups. The first group consisted of patients with sepsis (n=20), a second 
group of patients with septic shock (n=20) and a third group were critically ill patients 
without sepsis (n=20).  The first ACTH stimulation test was performed within 24 hours 
of the diagnosis of sepsis or septic shock in groups 1 and 2 or within 24 hours of ICU 
admission  in group 3 (day 1). A short corticotropin stimulation test was repeated 24 
hours after the first ACTH stimulation test (day 2) and individual cortisol responses in 
two ACTH tests were compared. Absolute adrenal insufficiency was defined as a 
maximum cortisol concentration of less than 500 nmol/l (18 Pg/dl) after the ACTH 
stimulation test (Bouachour 1995, Lamberts 1997) and an increase in the serum cortisol 
concentration of less than 248 nmol/l (9 Pg/dl) irrespective of basal cortisol level was 
used as the criterion for relative adrenal insufficiency (Annane 2000). 
 
   Study IV. Study IV was a multicenter prospective randomized study. In this study, 
metabolic and hemodynamic effects of two corticosteroid treatment modalities (bolus 
versus continuous hydrocortisone infusion) were compared. Special attention was 
focused on the blood glucose profiles, and the amount of nursing workload needed to 
maintain tight glycemic control during intensive insulin therapy. Serial hemodynamic 
measurements and the reversal of shock were also compared between the study groups. 
When patients were considered to benefit from the corticosteroid treatment, they were 
randomly assigned to receive hydrocortisone either by a conventional bolus therapy (50 
mg bolus of hydrocortisone every six hours intravenously) or by continuous infusion of 
the equivalent dose (200 mg/day). Hydrocortisone treatment was started according 
clinical judgement when patients required high-dose or increasing norepinephrine 
support (Keh 2004). Hydrocortisone was given as hydrocortisone sodium succinate, 
(Solu-Cortef®, Pharmacia, Puurs, Belgium). When continuous infusion was used 
hydrocortisone was diluted with physiologic saline. Randomization was performed in 
blocks of four patients by means of sequentially numbered opaque envelopes. Duration 
of hydrocortisone treatment was 5 days. After the randomization a maintenance infusion 
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of 5% glucose was started at the rate of 30 ml/kg/day. At the same time a protocol–
based enteral nutrition with standard formulas (1 kcal/ml) was initiated. Enteral feeding 
was started at 500 ml/day with daily increments of 500 ml if possible. The maximum 
amount of enteral nutrition was set at 1500 ml/day. Blood glucose levels were 
monitored every two hours. The goal was to maintain plasma glucose levels between 4 
and 7 mmol/l. When the plasma glucose level exceeded 7 mmol/l, an insulin infusion of 
1 IU/ml (Actrapid ®, Novo Nordisk A/S, Baksvaerd, Denmark) was started, and the 
dose was adjusted according to a strict algorithm (Table 8). 
 
 
Table 8. Algorithm for glucose control in study IV. 
1. Initial infusion   
Blood glucose Insulin infusion rate Control interval 
(mmol/l)  (hours) 
7.0-9.9 1 IU/hour 2 
10-11.9 2 IU/hour 1-2 
>12 4 IU/hour 1-2 
2. Maintenance infusion   
Blood glucose Insulin infusion rate Control interval  
(mmol/l)  (hours) 
<2.5 10% glucose 150 ml iv. 0.5 
<3.0 Stop insulin 1 
3.1-3.9 Reduce insulin dose by half 1 
4.0-4.9 Reduce by 0.5 IU/hour 2 
5.0-6.9 Insulin dose unchanged 2 
7.0-9.9 Increase by 0.5-1 IU/hour 2 
10-11.9 Increase by 1 IU/hour 2 
>12.0 Increase by 2 IU/hour 2 
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Laboratory assays 
 
   Short ACTH stimulation tests (I, III). In the studies I and III, a short corticotropin 
stimulation test was performed within 24 hours of the diagnosis of sepsis or septic 
shock or within 24 hours of ICU admission in nonseptic patients. Tetracosactin 0.25 mg 
(Synacthen£, Ciba-Geigy, France) was infused, and blood samples were taken 
immediately before the test for the determination of basal serum cortisol concentration 
and 30 and 60 minutes thereafter. After centrifugation serum samples were stored at 4 
ºC and analysed within 24 hrs. If the assay was delayed, samples were stored frozen at –
20 ºC. Cortisol was measured by fluoroimmunoassay in Tampere University Hospital 
and in Päijät-Häme Central Hospital; an enzyme immunoassay was used in Kuopio 
University Hospital. ACTH stimulation tests were obtained in the morning. Random 
cortisol measurements were also obtained 9.00 am.  
   Plasma ACTH measurements (I). Plasma ACTH levels were measured in patients 
with severe sepsis. Blood samples for the ACTH measurements were taken immediately 
before the ACTH stimulation test. Blood samples were drawn into EDTA tubes, 
centrifuged and stored frozen at –20 ºC. Adrenocorticotropic hormone analyses were 
performed using an immunoluminometric assay. 
   Plasma concentrations of IL-1, IL-6, IL-10 and IL-1 receptor antagonist (II). In 
study II blood samples for cytokine analyses were drawn into EDTA tubes, centrifuged 
and stored at –70°C. The cytokine analyses (IL-1, IL-10, IL-6) were performed using an 
ELISA immunoassay technique (Pelikine CompactTM, Central Laboratory of the 
Netherlands Red Cross Transfusion Service, Amsterdam, Netherlands). The IL-1ra 
assays were also performed with an enzyme immunoassay method (Quantikine, R&D 
Systems Inc, Minneapolis, USA). The detection limits for the cytokine assays were 0.4 
pg/ml for IL-1E, 0.6 pg/ml for IL-6, 1.2 pg/ml for IL-10, and 14 pg/ml for IL-1ra.  
   Plasma glucose measurements (IV). In study IV, blood glucose levels were 
monitored every two hours from the arterial line during the study period. Blood glucose 
measurements were performed with blood gas analyzers, and the results were expressed 
as plasma glucose levels. 
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Scoring methods for the severity of illness  
 
Acute Physiology and Chronic Health Evaluation (APACHE) II scores (Knaus 1985) 
and Simplified Acute Physiology Scores (SAPS) II (Le Gall 1993) were calculated and 
the severity of organ dysfunction was assessed using Sequential Organ Failure 
Assessment (SOFA) scores (Vincent 1996) at the time of ICU admission. In studies I 
and II SOFA score were calculated daily during the 10-day study period to assess the 
development and the resolution of organ failure. In sedated patients, the SOFA scores 
for neurological system were not graded. 
 
Statistical analysis 
 
The descriptive statistics are reported as mean values r SD. The patient groups were 
compared using the unpaired Student´s t-test for the continuous variables, and the Chi-
square test or the Fisher´s exact test for categorical data as appropriate. In study III, a 
one-way analysis of variance with Bonferroni’s test was used to compare the continuous 
variables between the groups. Analysis of variance (ANOVA) for repeated 
measurements was used in study I to compare serial SOFA scores between the groups 
and in study IV when blood glucose profiles, insulin requirements and serial 
hemodynamic data were compared. In study III, Pearson’s correlation coefficient was 
used to assess the correlation between the results of the ACTH stimulation tests on day 
1 and day 2. In study IV, Kaplan-Meier curves were calculated for shock reversal, and 
the comparison between the groups was performed with the log rank test. 
 
In study II, the cytokine measurements were not normally distributed, and therefore 
nonparametric tests were used. The within-group variations were analysed using 
Friedman´s test, and the differences between the groups were compared using the 
Mann-Whitney U-test. The cytokine levels are expressed as median values (range). In 
study IV, a sample size was calculated on the basis of detecting a difference of 1 mmol/l 
in mean blood glucose levels between the study groups. A standard deviation of 1 
mmol/l in blood glucose level was assumed when calculating a sample size based on 
previous studies (Van den Berghe 2001). A minimum of 17 patients was required in 
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each group (Į= 0.05, power = 80%). ICU mortality was expected to be 30%, and 
therefore 24 patients were randomized in both groups. P-values below 0.05 were 
considered significant. All Statistical analyses were performed using the SPSS Software 
(SPSS Inc. Chicago, USA). 
 
 
Ethical considerations 
 
All study protocols were approved by the local Ethics Committees.  Informed consent 
was obtained from the patients or their first-degree relatives. Studies I, II, III were 
prospective observational studies and no specific interventions were performed. Study 
IV was randomized, but not placebo-controlled study, and all patients who were 
considered to benefit from the hydrocortisone received the actual treatment. 
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5. RESULTS 
 
5.1. Incidence of adrenal insufficiency  
 
The incidence of adrenal dysfunction was investigated in patients with severe sepsis (I) 
and in patients with septic shock (III). In severe sepsis, six patients (15%) had relative 
adrenal insufficiency. One patient demonstrated absolute adrenal insufficiency 
(stimulated cortisol level < 500 nmol/l), and a total incidence of adrenal dysfunction 
was 17% (I). In septic shock, the incidence of relative adrenal dysfunction was 
considerably higher: 16 patients (40%) with septic shock had impaired adrenal function 
on the first ACTH stimulation test, two of these patients demonstrated absolute adrenal 
insufficiency. The diagnostic criteria for relative adrenal insufficiency were slightly 
different in study I and III. If the same specific diagnostic criteria for adrenal 
insufficiency for septic shock patients used in the study III were applied to the study I 
population, two additional patients with relative adrenal insufficiency would be 
identified. Therefore, the total incidence of adrenal insufficiency would be 22% in 
severe sepsis. 
 
5.2. Impact of adrenal function on the development and resolution of 
MOF 
 
The impact of adrenal function on the development and resolution of multiple organ 
failure was assessed in severe sepsis (I). In nonsurvivors, the SOFA scores remained 
elevated in both study groups, and no differences were detected during the ICU stay. In 
survivors, the SOFA scores declined in both study groups, but resolution of organ 
failure was more rapid in those patients who demonstrated an adequate adrenal response 
compared with patients with an inadequate response. The difference in the SOFA scores 
between study groups was statistically significant (p=0.029, ANOVA). The daily SOFA 
scores of the non-survivors are presented in Figure 3 and the corresponding scores for 
survivors in Figure 4.  
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Figure 3. Daily SOFA scores (mean ± SD) of nonsurvivors in the inadequate adrenal response (IAR) and 
in the adequate adrenal response (AAR) groups (Figure 1 in the original article [study I]). There were no 
statistical differences between groups (p=0.902, ANOVA).  
 
 
 
 
Figure 4. Daily SOFA scores (mean ± SD) of survivors in the inadequate adrenal response (IAR) and 
adequate adrenal response (AAR) groups (Figure 2 in the original article [study I]). The difference between 
the study groups during the study period was significant (p=0.029, ANOVA).  
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5.3. Impact of anti-inflammatory cytokines on the development of 
MOF 
 
The impact of the anti-inflammatory cytokine profile on the development and resolution 
of multiple organ failure was evaluated in severe sepsis (II). Elevated concentrations of 
IL-6 and IL-1ra were detected in all patients, whereas IL-10 levels were elevated in 
68% of the patients, and elevated IL-1E concentrations were found only in 38% of the 
patients. Fifteen (40%) of these patients developed severe MOF. The IL-6 levels were 
significantly higher in those patients who developed severe multiple organ failure and in 
the IL-6 levels remained elevated in these patients. In contrast, in those patients who did 
not develop MOF IL-6 concentrations decreased during the study period (Figure 5). The 
initial IL-10 levels were similar in both groups. In patients without severe MOF the IL-
10 concentrations decreased over the time, but in MOF patients IL-10 levels were 
elevated on day 5 (Figure 6). To compare the relations between the pro- and anti-
inflammatory responses, the IL-6/IL-10 and the IL-1E/IL-1ra ratios were studied. The 
median concentrations of IL-1ra were 2,200 times higher than those of IL-1E and no 
significant changes were seen in the IL-1E/IL-1ra ratios between the study groups. In 
contrast, the IL-6/IL-10 ratio remained low in patients who did not develop MOF, 
whereas in the MOF patients the IL-6/IL-10 ratio was significantly higher in the early 
phase of sepsis on days 1 and 3 (Figure 7).  
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Figure 5. IL-6 levels in patients with severe sepsis. No MOF represents the patient group without multiple 
organ failure (n=22) and MOF indicates patients who developed severe multiple organ failure (n=15). All 
patients were alive at day 5 and there are no missing cytokine data in the figure. IL-6 levels remained 
elevated in the MOF patients, whereas in the no MOF group a significant decrease was observed 
(p<0.001). The p-values in the figure represent the differences in cytokine levels between the study groups 
at each time point. The horizontal bars represent the median values (Figure 1 in the original article [study 
II]).  
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Figure 6. IL-10 levels in patients with severe sepsis. No MOF represents the patient group without 
multiple organ failure (n=22). MOF indicates patients who developed severe multiple organ failure (n=15). 
All patients were alive at day 5 and there are no missing cytokine data in the figure. In the MOF group, no 
significant changes were observed in IL-10 levels, whereas in the no MOF patients the levels declined 
(P=0.02 within the group). The P-value in the figure represents the difference in cytokine levels between 
the groups at the day 5. The horizontal bars represent the median values (Figure 2 in the original article 
[study II]). 
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Figure 7. IL-6/IL-10 ratios in patients with severe sepsis. No MOF represents the patient group without 
multiple organ failure (n=22). MOF indicates patients who developed severe multiple organ failure (n=15). 
IL-6/IL-10 levels were elevated in the MOF patients at day 1 and 3, whereas in the no MOF group the IL-
6/IL-10 ratios remained low. The P-values in the figure represents the difference in cytokine levels 
between the groups at day 1 and 3. The horizontal bars represent the median values (Figure 5 in the 
original article [study II]). 
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5.4. Reproducibility of the ACTH test  
 
The reproducibility of the ACTH stimulation test was investigated in 60 critically ill 
patients (III). The reproducibility of the test was good in patient with sepsis and in 
nonseptic patients. There was a good correlation in cortisol responses on day 1 and day 
2 among the nonseptic critically ill patients (Pearson’s correlation coefficient 0.69, 
p=0.001) (Figure 8). In patients with sepsis the correlation was rather good (Pearson’s 
correlation coefficient 0.54, p=0.014) (Figure 9). In septic shock patients no correlation 
between the two cortisol responses was observed (Pearson correlation coefficient 0.40, 
p=0.080) (Figure 10). 
 
 
 
 
 
 
 
 
Figure 8. Cortisol responses in the ACTH stimulation tests in nonseptic critically ill patients on days 1 and 
2 (Figure 2 from Study III). Correlation between cortisol responses was good (p=0.001). Dotted lines 
indicate the threshold of 248 nmol/l.  
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Figure 9. Cortisol responses in the ACTH stimulation tests in patients with sepsis on days 1 and 2 (Figure 
2 from Study III). Correlation was good in patients with sepsis (p=0.014). Dotted lines indicate the 
threshold of 248 nmol/l.  
 
 
 
Figure 10. Cortisol responses in the ACTH stimulation tests in patients with septic shock on days 1 and 2 
(Figure 2 from Study III). No correlation was observed (p=0.080). Dotted lines indicate the threshold of 248 
nmol/l.  
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 In patients with septic shock 5 out of 8 patients who had impaired adrenal response on 
the first day demonstrated a normal adrenal response on the second day, and six patients 
with septic shock (30%) who had a normal adrenal function on the first day 
demonstrated impaired adrenal function on the second day. An impaired adrenal 
response was seen in both stimulation tests only in three patients with septic shock; two 
of these patients had absolute adrenal insufficiency. 
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5.5. Comparison between continuous vs. bolus hydrocortisone infusion 
in septic shock  
 
 
Blood glucose profiles, insulin requirements, amount of nursing workload needed and 
shock reversal was compared in septic shock patients who were randomized to receive 
hydrocortisone treatment either by bolus or by continuous infusion. Mean daily blood 
glucose levels, insulin requirements and intake of calories were similar in both groups 
(Figures 11, 12 and 13). When insulin requirements were adjusted to administered 
calories, there was a trend for lower insulin requirements in the infusion group 
throughout the study period, but this difference was not statistically significant. 
 
 
 
 
 
 
Figure 11. Blood glucose levels (mean ± SD) in the study groups (Figure 2 in the original article [study 
IV]). No statistical difference between the study groups (p= 0.339, ANOVA). 
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Figure 12. Insulin requirements (mean ± SD) in the study groups (Figure 3 in the original article [study 
IV]). No statistical difference between the study groups (p= 0.908, ANOVA). 
 
 
 
 
 
Figure 13. Intake of calories (mean ± SD) in the study groups (Figure 4 in the original article [study IV]). 
No statistical difference between the study groups (p= 0.169, ANOVA). 
 73
The data concerning glycemic control is presented in Table 9.  Although the mean blood 
glucose levels were quite identical, the hyperglycemic (> 7 mmol/l) episodes were more 
common in bolus group than in infusion group (p=0.039). Severe hyperglycemia (blood 
glucose >8.3 mmol/l) was rare in both study groups, and also hypoglycemic episodes 
were uncommon. Three hypoglycemic (blood glucose < 3 mmol/l) episodes were 
observed in bolus group and only one in infusion group. Severe hypoglycemia (blood 
glucose < 2.2 mmol/l) was not observed in either study groups. The amount of nursing 
workload needed to maintain normoglycemia was higher in the bolus group: more 
insulin infusion rate adjustments were needed in the bolus group than in infusion treated 
patients (p = 0.038). 
 
 
Table 9. Glycemic control in the study groups (Table 3 in the original article [study IV]). 
 
 
Bolus group 
N = 23 
Infusion group 
N = 22 
p value 
 
Mean blood glucose (mmol/l) 6.4 r 0.7 6.2 r 0.7 0.040 
Blood glucose variation  
coefficient (%) 
 
20.2 ± 6.9 16.5 ± 4.8 0.063 
Blood glucose > 7 mmol/l 
(episodes / patient) 
 
15.7 r 8.5 10.5 r 8.6 0.039 
Blood glucose > 8.3 mmol/l 
(episodes / patient) 
 
3.6 r 3.4 2. 6 r 3.2 0.383 
Mean insulin dose (IU/day) 66 r 43 61 r 40 0.381 
Insulin infusion adjustments 
 (no / patient / day) 
 
4.7 ± 2.2 3.4 ± 1.9 0.038 
Blood glucose < 3 mmol/l 
(episodes / group) 
 
3 (13%) 1 (4.5%) 0.609 
Blood glucose < 2.2 mmol/l 
(episodes / group) 
 
0 0 n.s. 
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The reversal of shock was similar in both study groups. The vasopressor support could 
be withdrawn within 48 hrs in 14 (58%) of the patients in bolus group and the 
corresponding figure in the infusion group was 12 (50%). After 5 days vasopressors 
were withdrawn in 20 patients (83%) in bolus group and in 15 patients (63%) in the 
infusion group. Serial hemodynamic data are presented in Table 10. 
 
 
 
 
 
Table 10. Hemodynamic parameters in Study IV (Table 4 in the original article). 
 
 Day 1 Day 2 Day 3 Day 4 Day 5 p value 
 
Heart rate (1/min) 
Bolus group 
Infusion group 
107 r 20 
100 r 21 
93 r 20 
95 r 19 
85 r 20 
87 r 23 
78 r 22 
86 r 22 
86 r 21 
83 r 15 
 
0.93 
 
MAP (mmHg) 
Bolus group  
Infusion group 
62 r 7.5 
65 r 7.9 
75 r 12 
72 r 9.4 
79 r 13 
72 r 12 
85 r 15 
75 r 13 
87 r 15 
79 r 19 
 
0.06 
 
Cardiac index 
(l/min/m2) 
Bolus group 
Infusion group 
3.8 r 1.7 
3.6 r 1.5 
3.5 r 1.1 
3.9 r 1.3 
3.5 r 0.9 
3.5 r 1.1 
3.4 r 1.0 
3.6 r 1.3 
3.4 r 0.7 
3.8 r 1.5 
 
 
0.52 
 
SvO2 (%) 
Bolus group 
Infusion group 
61 r 7.6 
64 r 12 
67 r 7.2 
65 r 10 
69 r 7.3 
63 r 11 
70 r 7.6 
66 r 13 
69 r 7.0 
70 r 13 
 
0.50 
 
SVR (dyns /cm 5) 
Bolus group 
Infusion group 
623 r 221 
731 r 254 
770 r 323 
705 r 248 
861 r 249 
818 r 274 
999 r 334 
836 r 332 
1061 r 200 
 832 r 214 
 
0.55 
 
Shock reversal  
Bolus group 
Infusion group 
0 / 24 (0%) 
0 / 24 (0%) 
3 / 24 (13 %) 
5 / 24 (21 %) 
14 / 24 (58 %) 
12 / 24 (50 %) 
18 / 24 (75 %) 
14 / 24 (58 %) 
20 / 24 (83 %) 
15 / 24 (63 %) 
 
0.48 
 
MAP: mean arterial pressure, SVR: systemic vascular resistance; SvO2: mixed venous oxygen saturation.  P-values 
represent difference between the study groups (ANOVA and log rank test). 
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6. DISCUSSION 
 
6.1. Clinical significance of anti-inflammatory response  
 
The main purpose of this study was to investigate anti-inflammatory mechanisms in 
severe sepsis, to evaluate the clinical significance of the anti-inflammatory response and 
relative adrenal insufficiency and the limitations of the current diagnostic methods, and 
to compare different hydrocortisone treatment modalities in vasopressor-dependent 
septic shock. The results of this study demonstrated that both adequate adrenal function 
and IL-10 response seemed to have an important protective function in the 
pathophysiology of sepsis. Inadequate cortisol production and impaired IL-10 
production was associated with the development of severe MOF, poor resolution of 
organ dysfunction, longer ICU stay and increased mortality. This study also 
demonstrated that the current diagnostic methods are not optimal in the identification of 
patients who might benefit from hydrocortisone therapy. Especially in septic shock a 
single ACTH stimulation test could not accurately reveal patients who had impaired 
adrenal function, and the results of the two consecutive ACTH tests were poorly 
reproducible in patients with septic shock.  
 
There is a general agreement that the activation of the HPA axis functions as an 
important mechanism sustaining homeostasis in sepsis, but there is much controversy 
regarding the absolute levels of cortisol that are considered to be adequate in septic 
shock. Conflicting results have been published on the correlation between isolated 
plasma cortisol levels and patient prognosis. Both very high and low cortisol levels have 
been associated with increased mortality in sepsis, but in other studies no correlation 
has been observed (Sibbald 1977, Finlay 1982, Jurney 1987, Span 1992, Annane 2000).  
In general, it has been suggested that single plasma cortisol measurements have no 
predictive value on patient outcome (Schein 1990, Lippiner-Friedman 2007). The 
results in this study are accordance with these findings. Neither single nor serial cortisol 
measurements were useful in the assessment of adrenal reserve in severe sepsis. Even in 
situations where plasma cortisol levels are high, the decreased number or affinity of 
glucocorticoid receptors may contribute to glucocorticoid resistance in septic shock, and 
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patients may have functional cortisol deficiency (Huang 1987, Molijn 1995). The 
intracellular activity of cortisol may also be impaired due to changes in the activity of 
the type I and II 11ȕ-hydroxysteroid dehydrogenase enzymes, which catalyze the 
interconversion of active cortisol and inactive cortisone (Draper 2005).  
 
In addition to adequate cortisol production, sufficient IL-10 production also seemed to 
have protective function in the pathophysiology of multiple organ failure. Study II could 
not confirm the previously presented hypothesis of the role of overproduction of IL-10 
in the pathogenesis of MOF (Friedman 1997). In contrast, the findings in this study 
support the opposite concept that there is a relative IL-10 deficiency in MOF patients. 
Relatively low IL-10 levels may exacerbate the systemic inflammatory response. In 
zymosan-induced experimental MOF, the absence of endogenous IL-10 has enhanced 
the development of organ dysfunction (Malleo 2007). Several clinical reports also 
suggest that endogenous IL-10 production have protective effects during critical illness. 
High levels of IL-10 have been reported to be beneficial in critically ill patients with 
SIRS, ARDS and severe pancreatitis (Donelly 1996, Armstrong 1997, Simovic 1999, 
Taniguchi 1999). Taniguchi et al. have demonstrated that in patients with SIRS elevated 
IL-10 levels were observed both in survivors and nonsurvivors, but the IL-6/IL-10 ratio 
was significantly higher among the nonsurvivors (Taniguchi 1999), a similar finding 
which was observed in the present study. In addition to anti-inflammatory effects, IL-10 
also may be an important endogenous regulator of the activity of the HPA axis (Smith 
1999). An inadequate IL-10 response and relative adrenal insufficiency may therefore 
be linked together in sepsis.  
 
The incidence of relative adrenal insufficiency in severe sepsis was 22% (Study I) and 
in septic shock 40% (Study III). At present, data concerning the incidence of 
adrenocortical dysfunction in sepsis have substantial variation, because the exact criteria 
for relative adrenal insufficiency in critical illness are lacking. Due to the heterogeneity 
of the diagnostic methods in different studies, the incidences of adrenocortical 
insufficiency have varied between 0% and 55% in sepsis (Schein 1990, Soni 1995, 
Annane 2000, Oppert 2000). The most widely used criteria for relative adrenal 
insufficiency is a cortisol increment of < 250 nmol/l in the conventional ACTH test 
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irrespective of the basal cortisol concentration (Keh 2004). With this criterion, up to 
77% of the patients with refractory septic shock were considered to have relative 
adrenal failure (Annane 2002). However, if the basal cortisol levels are extremely high, 
it is probable that the cortisol response is blunted. Moran et al. demonstrated that 
cortisol response in ACTH simulation test was negatively correlated with the basal 
cortisol levels and in Oppert´s study majority of the patients who had basal cortisol 
levels above 1000 nmol/l the increment in cortisol was <250 nmol/l (Moran 1994, 
Oppert 2000). Whether this represents a maximally stimulated and appropriately 
functioning adrenal cortex or true relative adrenocortical insufficiency is still a matter 
for debate (Lamberts 1997, Marik 2000). 
 
Interpretation of the low-dose (1 ȝg) ACTH test has similar problems. Siraux and co-
workers performed both the low-dose and conventional ACTH test in 46 consecutive 
patients with sepsis shock. In their study the low-dose test identified a subgroup of 
patients with inadequate adrenal reserve who had a worse outcome and who would have 
missed by the high-dose test (Siraux 2005). The incidence of relative adrenal 
insufficiency was 68% in the low-dose test and 35% in the conventional test (Siraux 
2005). In a study by Salgado et al. the cortisol response was twice as high in the 
conventional test as in the low-dose test. Correspondingly, the incidence of relative 
adrenal insufficiency was significantly higher in the low-dose test (Salgado 2006). If the 
same diagnostic threshold is used for the diagnosis of adrenal dysfunction, it is evident 
that the incidence of adrenal dysfunction in the low-dose test is substantially higher. 
Similarly, there is no consensus which threshold for cortisol increment should be used 
in the low-dose ACTH test in critically ill patients. 
 
The most relevant finding in the present study concerning clinical practise was the 
finding that the results of ACTH stimulation tests were poorly reproducible in septic 
shock. This finding further questions the whole concept of relative adrenal 
insufficiency. No correlation was seen between the cortisol responses in two 
consecutive ACTH stimulation tests. Moreover, the majority of the septic shock patients 
who had a poor cortisol response on the first day demonstrated preserved adrenal 
function on the second day. Conversely, in six patients an adequate adrenal response on 
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the first day turned to be inadequate on the second day. Only in three patients impaired 
adrenal function was seen in both tests. These findings imply that in septic shock 
cortisol production may change rapidly over a short period of time. Analogous findings 
have been reported previously (Voerman 1992, Rydvall 2000). According to the present 
study, it is probable that the results of the ACTH stimulation test may also change very 
rapidly.  The poor reproducibility of the ACTH test in septic shock has been previously 
observed by Bouachour, and the results in study III confirm this finding (Bouachour 
1995). In contrast, the reproducibility of the ACTH stimulation test was good in 
nonseptic critically ill patients. It is therefore obvious that the rapid changes in 
adrenocortical function are related specifically to septic shock.  
 
The results obtained in study III shows that a single ACTH stimulation test can not 
identify all those patients who might benefit from hydrocortisone therapy, and there 
may be additional patients who will respond to corticosteroid therapy even if the results 
of the ACTH stimulation test are normal at the onset of septic shock. The value of the 
ACTH test in the assessment of adequacy of cortisol production has been recently 
questioned by several other authors. It has been suggested that its use could be limited 
for cases where the diagnosis of adrenal insufficiency is of special importance (Marik 
2003, Ligtenberg 2004, Morel 2006).  
 
Another confounding factor in the diagnosis of adrenal insufficiency is a variation in 
laboratory analysis. Cortisol immunoassays vary substantially. In general, there is a 
trend to obtain higher cortisol values than measured using the reference gas 
chromatography method (Vogeser 2005). In the CORTICUS trial, there was a 
considerable difference in the diagnosis of patients as responders, depending on the 
methodology. As a result, in approximately 20% of the patients the diagnosis of relative 
adrenal insufficiency could be missed due to laboratory inaccuracies (Briegel 2005).  
 
The concept of serum free cortisol has added further complexity to the diagnosis of 
adrenal dysfunction in septic shock. In healthy subjects more than 90% of circulating 
total cortisol is protein-bound to albumin and cortisol binding globulin (CBG), and only 
10% of the cortisol is present in the free form (Stewart 2003). This free cortisol is 
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considered to be the active form of the hormone and responsible for the physiological 
actions. Changes in the concentration of its carrier proteins can affect the concentration 
of the bound and unbound fraction of cortisol. In sepsis, decreased CBG and albumin 
levels are frequently observed. In these situations serum free cortisol levels are 
increased, even though at the same time the total serum cortisol levels seem to be 
inappropriately low (Arafah 2006). In the presence of hypoproteinemia, the majority of 
the patients may be incorrectly considered to have adrenal insufficiency, even though 
free cortisol levels are actually adequate (Hamrahian 2004). The data concerning free 
cortisol measurements in sepsis is currently very limited, and the technique for direct 
measurements for free cortisol is not available for routine clinical practise (Hamrahian 
2004, Ho 2006). 
 80
6.2. Therapeutic implications 
 
Currently, there is no consensus about whether the hydrocortisone therapy can be 
detrimental for some patients with sepsis shock, and whether patients whose adrenal 
function is normal should be excluded from corticosteroid therapy. In Annane´s study, 
there was tendency towards increased mortality in the treatment group among those 
patients who were responders in the ACTH test.  In critical illness, prolonged use of 
corticosteroids may increase the risk of metabolic and neuromuscular complications and 
hospital-acquired infections (Rady 2006). Especially the risk of critical illness 
polyneuropathy and myopathy is increased due to corticosteroid therapy, and the use of 
corticosteroids has been associated with protracted weaning from mechanical 
ventilation and increased need for tracheostomy (De Jonghe 2002, Rady 2006). Plasma 
concentrations of cortisol obtained during so-called low-dose hydrocortisone therapy 
are clearly higher than physiological plasma levels. The plasma cortisol concentrations 
by using constant hydrocortisone infusion are 2000– 3000 nmol/l, and the peak levels 
achieved after intravenous boluses are even higher, reaching values of 3000-4000 
nmol/l (Oppert 2000, Arafah 2006). 
 
The major adverse event associated with corticosteroid therapy is uncontrolled 
hyperglycemia. Hydrocortisone is a potent glucocorticoid. Hydrocortisone stimulates 
gluconeogenesis both in liver and in peripheral tissues, and it also exacerbates insulin 
resistance. In critical illness corticosteroid treatment induces hyperglycemia, and the 
frequency of insulin use increases with corticosteroid exposure (Rady 2006). Impaired 
glycemic control has been associated with increased mortality in heterogeneous 
population of critically ill patients (Krinsley 2003). Van den Berghe at al. showed that 
preventing hyperglycemia with insulin substantially improved outcome in critically ill 
surgical patients (Van den Berghe 2001). This survival benefit was also observed in a 
recent prospective study in medical ICU population who required ICU treatment for 
more than three days (Van den Berghe 2006). Prolonged hyperglycemia is also one 
possible pathophysiologic mechanism behind the development of critical illness 
polyneuropathy and myopathy (Bercker 2005). So far however, there is no evidence for 
what glucose level would be optimal for septic shock patients, and there is no clinical 
 81
study that has confirmed the beneficial effects of strict normoglycemia in sepsis (Cariou 
2004). A multicenter study in Germany was discontinued prematurely because of 
identical mortality rate in the intensive insulin and control group, and a greater 
incidence of hypoglycemia in the tight blood glucose group (Brunkhorst 2008). In 
severely ill ICU patients the risk of hypoglycemia seems to be higher than in 
postoperative patients, and patients with sepsis are especially vulnerable to 
hypoglycemia (Viresendorp 2006, Brunkhorst 2008). 
 
The result obtained in study IV give novel information on combining intensive insulin 
and hydrocortisone therapy in sepsis management. The goal of tight glycemic control is 
made more complicated by steroid-induced hyperglycemia. Study IV is the first 
prospective randomized trial that has investigated the metabolic effects of 
hydrocortisone treatment in septic shock patients. The results in this study demonstrate 
that continuous hydrocortisone infusion decreases the number of hyperglycemic 
episodes during intensive insulin therapy. This approach also reduces the amount of 
nursing workload required to maintain tight blood glucose control compared with 
conventional bolus application.  
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6.3. Limitations of the study 
 
These studies were performed over a relatively long period of time. The first two studies 
were performed in a surgical intensive unit between 1997 and 1999, whereas studies III 
and IV were carried out 2003-2006 in multidisciplinary intensive care units. A striking 
difference between the severity of illness and ICU mortality was observed in these 
studies. In the first two studies the severity of illness was substantially lower, but at the 
same time the ICU mortality was high. During these years various randomized 
controlled trials have shown that specific therapeutic measures can reduce morbidity 
and mortality in selected groups of critically ill patients. These therapeutic measures 
include early goal-directed therapy, low tidal volume ventilatory treatment, strict 
glycemic control, daily interruption of sedative agents and steroid replacement therapy 
in vasopressor-dependent septic shock (ARDS Network 2000, Kress 2000, Rivers 2001, 
Van den Berghe 2001, Annane 2002). In critically ill surgical patients, Hartl et al. 
showed that implementation of these therapeutic measures decreased ICU mortality. In 
this observational study, ICU mortality was unchanged between 1993 and 2001, but 
after 2001  mortality decreased markedly from 32% to 19%  after the implementation of 
these evidence-based strategies (Hartl 2006). The mortality figures in Hartl´s study are 
very similar to the mortality figures obtained in the present study. Other studies have 
also reported that the survival of septic shock patients has substantially improved during 
these years (Dombrovskiy 2005).  
 
In addition to the different mortality rates the severity of illness was also different in 
these studies. Both the APACHE II and SAPS II scores were substantially higher in 
studies III and IV. This difference is partly explained by the differences in the data 
collection methods between the studies. In the first two studies physiologic variables 
were recorded from manually kept ICU worksheets, whereas in studies III and IV 
clinical information management systems were in routine use. The increased sampling 
rate of hemodynamic values in clinical information systems results in higher severity 
scores, a higher risk of hospital death and lower standardized mortality ratio (Suistomaa 
2000). The differences in ICU admission and discharge policies and variations in the 
quality of ICU care may explain the differences in ICU performances over time 
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(Metnitz 2000). The relatively small sample size, especially in studies I and II, may 
have had a substantial influence on the results. The interpretation of the results in these 
studies should therefore be done with caution. 
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6.4. Future perspectives 
 
In 2002 the Society of Critical Care Medicine, the European Society of Intensive Care 
Medicine, and the International Sepsis Forum developed in collaboration a three-phase 
Surviving Sepsis Campaign.  The purpose of this campaign was to increase clinician 
and public awareness of the incidence of sepsis, to develop guidelines for the 
management of severe sepsis and to improve the standard of care and to decrease the 
mortality in severe sepsis by 25% in 5 years (Dellinger 2004). The Surviving Sepsis 
guidelines recommend low-dose corticosteroids in the treatment of vasopressor-
dependent septic shock, and over the last few years the use of steroids for patients in 
septic shock has increased (Keh 2004). Current evidence shows that hydrocortisone 
therapy has a significant effect on shock reversal, but the question whether this 
treatment has a true effect on patients prognosis is not fully established. Although there 
might be short-term benefits in decreasing mortality in certain subgroups of patients, 
there is a risk that use of steroids is associated with greater functional disabilities in 
survivors of ICU. Moreover, there is a need for the standardization of diagnostic testing 
and indications for hydrocortisone therapy in patients with septic shock.  The purpose of 
the recent randomized controlled CORTICUS study comparing hydrocortisone to 
placebo in septic shock was to develop a uniformly accepted diagnostic testing system 
for adrenal insufficiency, to create diagnostic criteria for adrenal insufficiency and to 
establish indications for corticosteroid therapy in septic shock. This study enrolled 500 
patients over 3 years from 52 European centers before the study was prematurely 
suspended. There was no difference in the overall 28-day mortality rate, although the 
duration of shock was shorter in patients who received corticosteroids (Sprung 2008). 
There was no apparent benefit for hydrocortisone replacement therapy in the subgroup 
of patients with relative adrenal insufficiency, as defined by the criteria of Annane.  
 
Evidence-based medicine is difficult to apply in critical care medicine and in the 
treatment of sepsis particular. Clear-cut positive results from large randomized 
controlled trials in severe sepsis are not abundant. Many of the interventions applied to 
the treatment of sepsis that have undergone testing  in general ICU population but not 
specifically in population with sepsis or septic shock. The mortality rate in vasopressor-
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dependent septic shock is still high. In this setting, many treatment strategies can not 
ethically be studied in a placebo-controlled trial. The current situation is that the most of 
the therapies applies to critically ill patients lack even grade B level of evidence, and in 
Surviving Sepsis Campaign guidelines, the evidence for most interventions the is only 
level E (Vincent 2004). Although the effect of a single therapeutic intervention on 
patient mortality is difficult to show in randomized controlled trials, several individual 
hospitals have successfully implemented Surviving Sepsis Campaign guidelines, and an 
improved outcome in septic shock has been reported in individual ICUs (Kortgen 2006, 
Micek 2006, Shapiro 2006). The findings of the present study also support the concept 
that the mortality from sepsis has been reduced in the 21st century. 
 
The concept that death from sepsis is attributable to an overstimulated immune system 
in the early phase of disease based on animal studies does not reflect the real clinical 
picture in humans (Fink 1990). The experimental studies used large doses of endotoxin 
to trigger systemic inflammatory response (Deitch 1998). Consequently, levels of 
circulating cytokines were exponentially higher in animals than they are in critically ill 
patients (Deitch 1998). Studies have shown that the frequency of an exaggerated 
inflammatory response is considerably lower than what it was originally thought to be. 
In clinical studies, many patients with severe sepsis frequently demonstrate undetectable 
levels for some cytokines (Damas 1991, Goldie 1995). This phenomenon was observed 
also in this study. Only one third of the patients had elevated IL-1ȕ levels during the 
whole study period, and in general, the cytokine concentrations were markedly lower 
than in experimental studies.  
 
Although anti-inflammatory reactions seem to have an important protective function in 
sepsis, individual patients may undergo many stages during which either pro- or anti-
inflammatory reactions may be dominant. Therefore therapies directed to attenuate 
inflammatory response may therefore be beneficial in some septic patients and 
deleterious in others (Marshall 2000). Age, immune status, type of infection and genetic 
predisposition modifies the inflammatory response during the intensive care period. One 
step forward to a better targeted therapy in the future would be a better characterization 
of both systemic inflammatory and compensatory anti-inflammatory reactions. So far, 
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however, the heterogeneous nature of sepsis and the complexity of the disease process 
make it difficult to characterize individual inflammatory response in everyday clinical 
practice.   
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7. CONCLUSIONS 
 
Based on these studies the following conclusions can be drawn. 
 
1. With the current diagnostic criteria, functional adrenal insufficiency is relatively 
common in sepsis. An impaired adrenal response at the onset of sepsis was observed in 
22% of the patients with severe sepsis and 40% of the patients with septic shock. In 
contrast, absolute adrenal insufficiency was uncommon. 
 
2. Endogenous anti-inflammatory reactions have an important role in the development 
and resolution of multiple organ failure. Both inadequate cortisol and IL-10 production 
were associated with the development of severe multiple organ failure, poor resolution 
of organ dysfunction, longer ICU stay and increased mortality 
 
3. In septic shock changes in adrenocortical function are very rapid. A single ACTH test 
is not reliable method in detecting inadequate cortisol production. Dichotomous 
categorization of adrenal function seems to be artificial in septic shock, and a single 
ACTH stimulation test can not identify accurately patients who might benefit from 
hydrocortisone therapy. If the results of the ACTH stimulation test are normal at the 
onset of septic shock, it is still possible that patients may develop adrenocortical 
dysfunction later during the ICU period.  
 
4.  Strict normoglycemia is more easily achieved if hydrocortisone therapy is given by 
continuous infusion to septic shock patients. Continuous hydrocortisone infusion will 
reduce the number of hyperglycemic episodes, and reduce the nursing workload during 
intensive insulin therapy. The differences between the study groups were rather 
marginal, and in both groups the normoglycemic goal could be achieved quite 
successfully.  Slightly more liberal glucose control than in the original intensive insulin 
therapy trials very effectively prevented severe hypoglycemic episodes. 
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